<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><?covid-19-tdm ?><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">85680</article-id><article-id pub-id-type="doi">10.7554/eLife.85680</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Epidemiology and Global Health</subject></subj-group></article-categories><title-group><article-title>A rapid review of COVID-19’s global impact on breast cancer screening participation rates and volumes from January to December 2020</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-304389"><name><surname>Lee</surname><given-names>Reagan</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-3658-4103</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-221670"><name><surname>Xu</surname><given-names>Wei</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0009-0008-3338-4545</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-304390"><name><surname>Dozier</surname><given-names>Marshall</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-5151-1252</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-304391"><name><surname>McQuillan</surname><given-names>Ruth</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-0998-9540</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-180352"><name><surname>Theodoratou</surname><given-names>Evropi</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-289733"><name><surname>Figueroa</surname><given-names>Jonine</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-5100-623X</contrib-id><email>jonine.figueroa@ed.ac.uk</email><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><on-behalf-of>On Behalf of UNCOVER and the International Partnership for Resilience in CancerSystems (I-PaRCS), Breast Cancer Working Group 2</on-behalf-of><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01nrxwf90</institution-id><institution>Usher Institute, University of Edinburgh</institution></institution-wrap><addr-line><named-content content-type="city">Edinburgh</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01nrxwf90</institution-id><institution>Centre for Global Health, University of Edinburgh</institution></institution-wrap><addr-line><named-content content-type="city">Edinburgh</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01nrxwf90</institution-id><institution>Information Services, University of Edinburgh</institution></institution-wrap><addr-line><named-content content-type="city">Edinburgh</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/040gcmg81</institution-id><institution>Division of Cancer Epidemiology and Genetics, National Cancer Institute</institution></institution-wrap><addr-line><named-content content-type="city">Bethesda</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Meza</surname><given-names>Rafael</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00jmfr291</institution-id><institution>Univeristy of Michigan</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Franco</surname><given-names>Eduardo L</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01pxwe438</institution-id><institution>McGill University</institution></institution-wrap><country>Canada</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>12</day><month>09</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>12</volume><elocation-id>e85680</elocation-id><history><date date-type="received" iso-8601-date="2022-12-20"><day>20</day><month>12</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2023-08-20"><day>20</day><month>08</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at .</event-desc><date date-type="preprint" iso-8601-date="2023-02-06"><day>06</day><month>02</month><year>2023</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2023.02.06.23285513"/></event></pub-history><permissions><ali:free_to_read/><license xlink:href="http://creativecommons.org/publicdomain/zero/1.0/"><ali:license_ref>http://creativecommons.org/publicdomain/zero/1.0/</ali:license_ref><license-p>This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">Creative Commons CC0 public domain dedication</ext-link>.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-85680-v2.pdf"/><abstract><p>COVID-19 has strained population breast mammography screening programs that aim to diagnose and treat breast cancers earlier. As the pandemic has affected countries differently, we aimed to quantify changes in breast screening volume and uptake during the first year of COVID-19 . We systematically searched Medline, the World Health Organization (WHO) COVID-19 database, and governmental databases. Studies covering January 2020 to March 2022 were included. We extracted and analyzed data regarding study methodology, screening volume, and uptake. To assess for risk of bias, we used the Joanna Briggs Institute (JBI) Critical Appraisal Tool. Twenty-six cross-sectional descriptive studies (focusing on 13 countries/nations) were included out of 935 independent records. Reductions in screening volume and uptake rates were observed among eight countries. Changes in screening participation volume in five nations with national population-based screening ranged from –13 to –31%. Among two countries with limited population-based programs, the decline ranged from –61 to –41%. Within the USA, population participation volumes varied ranging from +18 to –39%, with suggestion of differences by insurance status (HMO, Medicare, and low-income programs). Almost all studies had high risk of bias due to insufficient statistical analysis and confounding factors. The extent of COVID-19-induced reduction in breast screening participation volume differed by region and data suggested potential differences by healthcare setting (e.g., national health insurance vs. private healthcare). Recovery efforts should monitor access to screening and early diagnosis to determine whether prevention services need strengthening to increase the coverage of disadvantaged groups and reduce disparities.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>breast cancer</kwd><kwd>screening</kwd><kwd>neoplasm</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>Jonine Figueroa research is supported by the intramural program</award-id><principal-award-recipient><name><surname>Figueroa</surname><given-names>Jonine</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>A reduction in breast screening participation volume during COVID-19 that differed by region and healthcare setting was observed in a rapid review of 26 studies globally, suggesting monitoring of screening access by disadvantaged groups to reduce disparities.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Breast cancer is the most common cancer worldwide, with 2.3 million cases diagnosed and 685,000 deaths in 2020 (<xref ref-type="bibr" rid="bib59">WHO, 2021</xref>). Mammography-based screening programs allow for early detection of breast cancers for earlier intervention and disease stage that improves patient outcomes (<xref ref-type="bibr" rid="bib26">IARC, 2022</xref>). Early detection and diagnosis from screening may reduce mortality by up to 65% among breast cancer patients (<xref ref-type="bibr" rid="bib3">Berry et al., 2005</xref>). Populations with a good uptake rate in screening programs can achieve a 90% 5-year survival rate in patients who received an early diagnosis attributed to screening (<xref ref-type="bibr" rid="bib59">WHO, 2021</xref>).</p><p>COVID-19 affected global health systems and has strained population breast mammography screening programs. Previous work on modeled evaluations and a focus on tumor staging and mortality as outcomes suggested that scenarios are likely to differ by region and organization of delivery of breast cancer screening (<xref ref-type="bibr" rid="bib22">Figueroa et al., 2021</xref>). In different countries, screening models vary from population-based to opportunistic screening (offered to patients in healthcare settings – more common in private healthcare) (<xref ref-type="bibr" rid="bib25">IARC, 2016</xref>).</p><p>Here we aimed to quantify systematically breast screening participation rates before and after the first COVID-19 wave amidst the suspensions in nations with/without opportunistic screening programs. This was performed by investigating two primary study outcomes: changes in screening volume and participation uptake rates.</p></sec><sec id="s2" sec-type="results"><title>Results</title><p><xref ref-type="fig" rid="fig1">Figure 1</xref> summarizes the search strategy. The initial search retrieved 1207 articles and 935 independent records. After screening (see ‘Methods’), 26 cross-sectional studies from 13 countries were eligible for inclusion (<xref ref-type="table" rid="table1">Table 1</xref>). We counted Scotland and England as two separate national entities due to the devolved healthcare systems. However, it should be noted that breast screening policies and practice between NHS Scotland and NHS England are similar. In total, 7 reports came from Europe (<xref ref-type="bibr" rid="bib7">Campbell et al., 2021</xref>; <xref ref-type="bibr" rid="bib27">Jidkova et al., 2022</xref>; <xref ref-type="bibr" rid="bib28">Knoll et al., 2022</xref>; <xref ref-type="bibr" rid="bib20">Eijkelboom et al., 2021</xref>; <xref ref-type="bibr" rid="bib32">Losurdo et al., 2022</xref>; <xref ref-type="bibr" rid="bib54">Toss et al., 2021</xref>; <xref ref-type="bibr" rid="bib38">NHS England, 2021</xref>), 2 from Oceania (<xref ref-type="bibr" rid="bib6">BreastScreen Australia, 2020</xref>; <xref ref-type="bibr" rid="bib5">BreastScreen Aoteroa, 2022</xref>), 1 from Asia (<xref ref-type="bibr" rid="bib47">Shen et al., 2022</xref>), 2 from South America (<xref ref-type="bibr" rid="bib4">Bessa, 2021</xref>; <xref ref-type="bibr" rid="bib44">Ribeiro et al., 2022</xref>), and 14 from North America (<xref ref-type="bibr" rid="bib9">Chiarelli et al., 2021</xref>; <xref ref-type="bibr" rid="bib58">Walker et al., 2021</xref>; <xref ref-type="bibr" rid="bib19">Doubova et al., 2021</xref>; <xref ref-type="bibr" rid="bib8">Chen et al., 2021</xref>; <xref ref-type="bibr" rid="bib1">Amornsiripanitch et al., 2021</xref>; <xref ref-type="bibr" rid="bib2">Becker et al., 2021</xref>; <xref ref-type="bibr" rid="bib15">DeGroff et al., 2021</xref>; <xref ref-type="bibr" rid="bib16">Dennis et al., 2021</xref>; <xref ref-type="bibr" rid="bib21">Fedewa et al., 2021</xref>; <xref ref-type="bibr" rid="bib29">Lehman et al., 2022</xref>; <xref ref-type="bibr" rid="bib31">London et al., 2022</xref>; <xref ref-type="bibr" rid="bib36">Miller et al., 2021</xref>; <xref ref-type="bibr" rid="bib49">Sprague et al., 2021</xref>; <xref ref-type="bibr" rid="bib39">Nyante et al., 2021</xref>). The most frequently reported country was the USA (n = 11). Studies examined either regional (n = 13) or national populations (n = 13).</p><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>PRISMA Flow Diagram for Record Identification, Screening and Inclusion for Analysis (<xref ref-type="bibr" rid="bib42">Page et al., 2021</xref>).</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85680-fig1-v2.tif"/></fig><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Descriptive characteristics of included cross-sectional studies (n = 26).</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Study</th><th align="left" valign="bottom">Publication type</th><th align="left" valign="bottom">Study design</th><th align="left" valign="bottom">Country</th><th align="left" valign="bottom">Region (If not national)</th><th align="left" valign="bottom" rowspan="2">Total Female Population of Study Area</th><th align="left" valign="bottom" rowspan="2">Sample size</th><th align="left" valign="bottom" rowspan="2">Study screening data source</th><th align="left" valign="bottom" rowspan="2">Screening (National/Regional)</th><th align="left" valign="bottom" rowspan="2">Screening age range</th><th align="left" valign="bottom" rowspan="2">Screening type</th><th align="left" valign="bottom" rowspan="2">Screening time comparison</th><th align="left" valign="bottom" colspan="8">Types of Restrictions present over study period<xref ref-type="table-fn" rid="table1fn3"><sup>†</sup></xref></th><th align="left" valign="bottom" colspan="2">COVID-19 7 day new infection rate in region of focus (per 100000)<xref ref-type="table-fn" rid="table1fn2">*</xref></th></tr><tr><th align="left" valign="bottom"/><th align="left" valign="bottom"/><th align="left" valign="bottom"/><th align="left" valign="bottom"/><th align="left" valign="bottom"/><th align="left" valign="bottom">International Travel Limits</th><th align="left" valign="bottom">Internal Movement Controls</th><th align="left" valign="bottom">Stay at home requirement</th><th align="left" valign="bottom">Public transport closure</th><th align="left" valign="bottom">Ban on gatherings of &gt;10 people</th><th align="left" valign="bottom">Public events ban</th><th align="left" valign="bottom">Workplace closure</th><th align="left" valign="bottom">School closure</th><th align="left" valign="bottom">Minimum infection rate in study period</th><th align="left" valign="bottom">Maximum infection rate in study period</th></tr></thead><tbody><tr><td align="left" valign="bottom">Europe (n=7)</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib7">Campbell et al., 2021</xref></td><td align="left" valign="bottom">Peer- reviewed</td><td align="left" valign="bottom">Cross sectional</td><td align="left" valign="bottom">Scotland (UK)</td><td align="left" valign="bottom"/><td align="left" valign="bottom">2728000</td><td align="left" valign="bottom">Not specified</td><td align="left" valign="bottom">NHS Scotland</td><td align="left" valign="bottom">National</td><td align="char" char="ndash" valign="bottom">50–70</td><td align="left" valign="bottom">Digital Mammography</td><td align="left" valign="bottom">Aug – Dec 2019 vs Aug -Dec 2020</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">No</td><td align="char" char="." valign="bottom">10.14</td><td align="char" char="." valign="bottom">212.67</td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib27">Jidkova et al., 2022</xref></td><td align="left" valign="bottom">Peer- reviewed</td><td align="left" valign="bottom">Cross sectional</td><td align="left" valign="bottom">Belgium</td><td align="left" valign="bottom">Flanders</td><td align="left" valign="bottom">3382265</td><td align="left" valign="bottom">Not specified</td><td align="left" valign="bottom">Flanders Online Screening Database</td><td align="left" valign="bottom">Regional</td><td align="char" char="ndash" valign="bottom">50–69</td><td align="left" valign="bottom">Digital Mammography</td><td align="left" valign="bottom">Jul – Nov 2019 vs Jul – Nov 2020</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="char" char="." valign="bottom">3.58</td><td align="char" char="." valign="bottom">580.63</td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib28">Knoll et al., 2022</xref></td><td align="left" valign="bottom">Preprint</td><td align="left" valign="bottom">Cross sectional</td><td align="left" valign="bottom">Austria</td><td align="left" valign="bottom">Innsbruck</td><td align="left" valign="bottom">567300</td><td align="left" valign="bottom">596</td><td align="left" valign="bottom">Database from gynecological oncological center in Austria, Tyrol</td><td align="left" valign="bottom">Local</td><td align="left" valign="bottom">45–69 years invited for screening. Women aged 40–44 years and 70–75 years may opt in</td><td align="left" valign="bottom">Digital Mammography</td><td align="left" valign="bottom">Mar – Dec 2019 vs Mar – Dec 2020</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">no data</td><td align="left" valign="bottom">no data</td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib20">Eijkelboom et al., 2021</xref></td><td align="left" valign="bottom">Peer- reviewed</td><td align="left" valign="bottom">Cross sectional</td><td align="left" valign="bottom">Netherlands</td><td align="left" valign="bottom"/><td align="left" valign="bottom">8701000</td><td align="left" valign="bottom">3371</td><td align="left" valign="bottom">Netherlands Cancer Registry</td><td align="left" valign="bottom">National</td><td align="char" char="ndash" valign="bottom">50–75</td><td align="left" valign="bottom">Digital Mammography</td><td align="left" valign="bottom">Jan – Feb 2020 vs Jul – Aug 2020</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">No</td><td align="char" char="." valign="bottom">0.32</td><td align="char" char="." valign="bottom">67.25</td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib32">Losurdo et al., 2022</xref></td><td align="left" valign="bottom">Peer- reviewed</td><td align="left" valign="bottom">Cross sectional</td><td align="left" valign="bottom">Italy</td><td align="left" valign="bottom">Friuli Venezia Giulia</td><td align="left" valign="bottom">624418</td><td align="left" valign="bottom">58643</td><td align="left" valign="bottom">“Data-Breast” database of the “Eusoma certified SSD Breast Unit of Trieste and from the Surgical Department of DAI Chirurgia Generale—ASUGI.</td><td align="left" valign="bottom">Regional</td><td align="char" char="ndash" valign="bottom">50–69</td><td align="left" valign="bottom">Digital Mammography</td><td align="left" valign="bottom">Oct – Dec 2019 vs Oct – Dec 2020</td><td align="left" valign="bottom">Yes<xref ref-type="table-fn" rid="table1fn4"><sup>‡</sup></xref></td><td align="left" valign="bottom">Yes<xref ref-type="table-fn" rid="table1fn4"><sup>‡</sup></xref></td><td align="left" valign="bottom">Yes<xref ref-type="table-fn" rid="table1fn4"><sup>‡</sup></xref></td><td align="left" valign="bottom">No<xref ref-type="table-fn" rid="table1fn4"><sup>‡</sup></xref></td><td align="left" valign="bottom">Yes<xref ref-type="table-fn" rid="table1fn4"><sup>‡</sup></xref></td><td align="left" valign="bottom">Yes<xref ref-type="table-fn" rid="table1fn4"><sup>‡</sup></xref></td><td align="left" valign="bottom">Yes<xref ref-type="table-fn" rid="table1fn4"><sup>‡</sup></xref></td><td align="left" valign="bottom">Yes<xref ref-type="table-fn" rid="table1fn4"><sup>‡</sup></xref></td><td align="char" char="." valign="bottom">19.2</td><td align="char" char="." valign="bottom">497.6</td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib54">Toss et al., 2021</xref></td><td align="left" valign="bottom">Peer- reviewed</td><td align="left" valign="bottom">Cross sectional</td><td align="left" valign="bottom">Italy</td><td align="left" valign="bottom">Northern Italy, Emilia Romagna</td><td align="left" valign="bottom">2291000</td><td align="left" valign="bottom">24994</td><td align="left" valign="bottom">Emilia Romagna National Healthcare System</td><td align="left" valign="bottom">Regional</td><td align="char" char="ndash" valign="bottom">45–79</td><td align="left" valign="bottom">Digital Mammography</td><td align="char" char="." valign="bottom">2019 vs 2020</td><td align="left" valign="bottom">Yes<xref ref-type="table-fn" rid="table1fn4"><sup>‡</sup></xref></td><td align="left" valign="bottom">Yes<xref ref-type="table-fn" rid="table1fn4"><sup>‡</sup></xref></td><td align="left" valign="bottom">Yes<xref ref-type="table-fn" rid="table1fn4"><sup>‡</sup></xref></td><td align="left" valign="bottom">Yes<xref ref-type="table-fn" rid="table1fn4"><sup>‡</sup></xref></td><td align="left" valign="bottom">Yes<xref ref-type="table-fn" rid="table1fn4"><sup>‡</sup></xref></td><td align="left" valign="bottom">Yes<xref ref-type="table-fn" rid="table1fn4"><sup>‡</sup></xref></td><td align="left" valign="bottom">Yes<xref ref-type="table-fn" rid="table1fn4"><sup>‡</sup></xref></td><td align="left" valign="bottom">Yes<xref ref-type="table-fn" rid="table1fn4"><sup>‡</sup></xref></td><td align="char" char="." valign="bottom">4.00</td><td align="char" char="." valign="bottom">390.9</td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib38">NHS England, 2021</xref></td><td align="left" valign="bottom">Government paper</td><td align="left" valign="bottom">Cross sectional</td><td align="left" valign="bottom">England (UK)</td><td align="left" valign="bottom"/><td align="left" valign="bottom">33940000</td><td align="left" valign="bottom">2230000</td><td align="left" valign="bottom">NHS England</td><td align="left" valign="bottom">National</td><td align="char" char="ndash" valign="bottom">50–71</td><td align="left" valign="bottom">Digital Mammography</td><td align="char" char="." valign="bottom">2019 vs 2020</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="char" char="." valign="bottom">0.00</td><td align="char" char="." valign="bottom">92.36</td></tr><tr><td align="left" valign="bottom" colspan="22">Oceania (n=2)</td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib6">BreastScreen Australia, 2020</xref></td><td align="left" valign="bottom">Government Paper</td><td align="left" valign="bottom">Cross sectional</td><td align="left" valign="bottom">Australia</td><td align="left" valign="bottom"/><td align="left" valign="bottom">12780000</td><td align="left" valign="bottom">Not specified</td><td align="left" valign="bottom">BreastScreen Australia</td><td align="left" valign="bottom">National</td><td align="char" char="ndash" valign="bottom">50–74</td><td align="left" valign="bottom">Digital Mammography</td><td align="left" valign="bottom">May – Sep 2018 vs May – Sep 2020</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="char" char="." valign="bottom">0.18</td><td align="char" char="." valign="bottom">13.31</td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib5">BreastScreen Aoteroa, 2022</xref></td><td align="left" valign="bottom">Government Paper</td><td align="left" valign="bottom">Cross sectional</td><td align="left" valign="bottom">New Zealand</td><td align="left" valign="bottom"/><td align="left" valign="bottom">2497000</td><td align="left" valign="bottom">Not specified</td><td align="left" valign="bottom">BreastScreen Aotearoa</td><td align="left" valign="bottom">National</td><td align="char" char="ndash" valign="bottom">45–69</td><td align="left" valign="bottom">Digital Mammography</td><td align="left" valign="bottom">May – Dec 2018 vs May - Dec 2020</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="char" char="." valign="bottom">0</td><td align="char" char="." valign="bottom">1.06</td></tr><tr><td align="left" valign="bottom" colspan="22">Asia (n=1)</td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib47">Shen et al., 2022</xref></td><td align="left" valign="bottom">Peer- reviewed</td><td align="left" valign="bottom">Cross sectional</td><td align="left" valign="bottom">China</td><td align="left" valign="bottom">Taiwan</td><td align="left" valign="bottom">11981657</td><td align="left" valign="bottom">699911</td><td align="left" valign="bottom">Taiwan National Infectious Disease Statistics system</td><td align="left" valign="bottom">Regional</td><td align="char" char="ndash" valign="bottom">40–69</td><td align="left" valign="bottom">Digital Mammography</td><td align="left" valign="bottom">Jan – Apr 2019 vs Jan – Apr 2020</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">no data</td><td align="left" valign="bottom">no data</td></tr><tr><td align="left" valign="bottom" colspan="22">Americas (n=16)</td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib4">Bessa, 2021</xref></td><td align="left" valign="bottom">Peer- reviewed</td><td align="left" valign="bottom">Cross sectional</td><td align="left" valign="bottom">Brazil</td><td align="left" valign="bottom"/><td align="left" valign="bottom">106500000</td><td align="left" valign="bottom">(2019: 20636636; 2020: 21140958)</td><td align="left" valign="bottom">Brazilian Unified Health System (SUS)</td><td align="left" valign="bottom">National</td><td align="char" char="ndash" valign="bottom">50–69</td><td align="left" valign="bottom">Digital Mammography</td><td align="char" char="." valign="bottom">2019 vs 2020</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="char" char="." valign="bottom">0.00</td><td align="char" char="." valign="bottom">149.68</td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib44">Ribeiro et al., 2022</xref></td><td align="left" valign="bottom">Peer- reviewed</td><td align="left" valign="bottom">Cross sectional</td><td align="left" valign="bottom">Brazil</td><td align="left" valign="bottom"/><td align="left" valign="bottom">106500000</td><td align="left" valign="bottom">5996798</td><td align="left" valign="bottom">Brazilian National Health Service (SUS) Outpatient Information System (SIA/SUS), SUS Hospital Information System (SIH/SUS), High Complexity Procedure Authorizations database (APAC), Cancer Information System (ISCAN).</td><td align="left" valign="bottom">National</td><td align="char" char="ndash" valign="bottom">50–69</td><td align="left" valign="bottom">Digital Mammography</td><td align="left" valign="bottom">Jul – Dec 2019 vs Jul – Dec 2020</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="char" char="." valign="bottom">53.72</td><td align="char" char="." valign="bottom">149.68</td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib9">Chiarelli et al., 2021</xref></td><td align="left" valign="bottom">Peer- reviewed</td><td align="left" valign="bottom">Cross sectional</td><td align="left" valign="bottom">Canada</td><td align="left" valign="bottom">Ontario</td><td align="left" valign="bottom">7371000</td><td align="left" valign="bottom">426967</td><td align="left" valign="bottom">Ontario Breast Screening Program (OBSP)</td><td align="left" valign="bottom">Regional</td><td align="char" char="ndash" valign="bottom">50–74</td><td align="left" valign="bottom">Digital Mammography, MRI (High risk)</td><td align="left" valign="bottom">Jul - Dec 2019 vs Jul - Dec 2020</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="char" char="." valign="bottom">3.99</td><td align="char" char="." valign="bottom">117.01</td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib58">Walker et al., 2021</xref></td><td align="left" valign="bottom">Peer- reviewed</td><td align="left" valign="bottom">Cross sectional</td><td align="left" valign="bottom">Canada</td><td align="left" valign="bottom">Ontario</td><td align="left" valign="bottom">7371000</td><td align="left" valign="bottom">605889 (2019) 284242 (2020)</td><td align="left" valign="bottom">Ontario Breast Screening Program (OBSP)</td><td align="left" valign="bottom">Regional</td><td align="char" char="ndash" valign="bottom">50–74</td><td align="left" valign="bottom">Digital Mammography</td><td align="left" valign="bottom">Modelled 2019 data vs Dec 2020</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="char" char="." valign="bottom">75.74</td><td align="char" char="." valign="bottom">117.01</td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib19">Doubova et al., 2021</xref></td><td align="left" valign="bottom">Peer- reviewed</td><td align="left" valign="bottom">Cross sectional</td><td align="left" valign="bottom">Mexico</td><td align="left" valign="bottom"/><td align="left" valign="bottom">64570000</td><td align="left" valign="bottom">1431216</td><td align="left" valign="bottom">Mexican Institute of Social Security (IMSS)</td><td align="left" valign="bottom">National</td><td align="left" valign="bottom">40 - unspecified</td><td align="left" valign="bottom">Digital Mammography</td><td align="left" valign="bottom">Jan 2019 – Mar 2020 vs Apr – Dec 2020</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="char" char="." valign="bottom">2.60</td><td align="char" char="." valign="bottom">61.12</td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib8">Chen et al., 2021</xref></td><td align="left" valign="bottom">Peer- reviewed</td><td align="left" valign="bottom">Cross sectional</td><td align="left" valign="bottom">USA</td><td align="left" valign="bottom"/><td align="left" valign="bottom">167500000</td><td align="left" valign="bottom">Not specified</td><td align="left" valign="bottom">HealthCore Integrated Research Database</td><td align="left" valign="bottom">National</td><td align="char" char="ndash" valign="bottom">50–79 years</td><td align="left" valign="bottom">Digital Mammography</td><td align="left" valign="bottom">Jul 2019 vs Jul 2020</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="char" char="." valign="bottom">119.03</td><td align="char" char="." valign="bottom">142.00</td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib1">Amornsiripanitch et al., 2021</xref></td><td align="left" valign="bottom">Peer- reviewed</td><td align="left" valign="bottom">Cross sectional</td><td align="left" valign="bottom">USA</td><td align="left" valign="bottom">Massachusetts</td><td align="left" valign="bottom">3537000</td><td align="left" valign="bottom">32387</td><td align="left" valign="bottom">Electronic medical record (Epic, Verona, WI) - Massachusetts. One tertiary care academic center, a community hospital, a specialized cancer center, three outpatient imaging centers, one urban healthcare center, and one mobile mammography van</td><td align="left" valign="bottom">Regional</td><td align="left" valign="bottom">40 - unspecified years</td><td align="left" valign="bottom">Digital Mammography</td><td align="left" valign="bottom">Jun – Aug 2019 vs Jun – Aug 2020</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td><td align="char" char="." valign="bottom">17.06</td><td align="char" char="." valign="bottom">53.09</td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib2">Becker et al., 2021</xref></td><td align="left" valign="bottom">Peer- reviewed</td><td align="left" valign="bottom">Cross sectional</td><td align="left" valign="bottom">USA</td><td align="left" valign="bottom">Michigan</td><td align="left" valign="bottom">5062000</td><td align="left" valign="bottom">7250080</td><td align="left" valign="bottom">Women enrolled in Health Managed Organization (HMO) Blue Cross Blue Shield (BCBS) in Michigan</td><td align="left" valign="bottom">Regional</td><td align="char" char="ndash" valign="bottom">40–74</td><td align="left" valign="bottom">Digital Mammography</td><td align="left" valign="bottom">Dec 2019 vs Dec 2020</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="char" char="." valign="bottom">147.56</td><td align="char" char="." valign="bottom">328.94</td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib15">DeGroff et al., 2021</xref></td><td align="left" valign="bottom">Peer- reviewed</td><td align="left" valign="bottom">Cross sectional</td><td align="left" valign="bottom">USA</td><td align="left" valign="bottom"/><td align="left" valign="bottom">167500000</td><td align="left" valign="bottom">630264</td><td align="left" valign="bottom">Breast and Cervical Cancer Early Detection Program (NBCCEDP) Database, which provides cancer screening services to women with low income and inadequate health insurance</td><td align="left" valign="bottom">National</td><td align="char" char="ndash" valign="bottom">40–74</td><td align="left" valign="bottom">Digital Mammography</td><td align="left" valign="bottom">Jun 2019 vs Jun 2020</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="char" char="." valign="bottom">45.46</td><td align="char" char="." valign="bottom">103.84</td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib16">Dennis et al., 2021</xref></td><td align="left" valign="bottom">Peer- reviewed</td><td align="left" valign="bottom">Cross sectional</td><td align="left" valign="bottom">USA</td><td align="left" valign="bottom"/><td align="left" valign="bottom">167500000</td><td align="left" valign="bottom">475083</td><td align="left" valign="bottom">Behavioral Risk Factor Surveillance System (BRFSS) survey database</td><td align="left" valign="bottom">National</td><td align="char" char="ndash" valign="bottom">40–74</td><td align="left" valign="bottom">Digital Mammography</td><td align="char" char="ndash" valign="bottom">2014–2019 vs 2020</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="char" char="." valign="bottom">0.00</td><td align="char" char="." valign="bottom">460.68</td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib21">Fedewa et al., 2021</xref></td><td align="left" valign="bottom">Peer- reviewed</td><td align="left" valign="bottom">Cross sectional</td><td align="left" valign="bottom">USA</td><td align="left" valign="bottom"/><td align="left" valign="bottom">167500000</td><td align="left" valign="bottom">2019:142003 2020:150630</td><td align="left" valign="bottom">Data from 32 CHCs of the American Cancer Society's Community Health Advocates Implementing Nationwide Grants for Empowerment and Equity (CHANGE) grant program to increase BCSRs and follow-up care</td><td align="left" valign="bottom">National</td><td align="char" char="ndash" valign="bottom">50–74</td><td align="left" valign="bottom">Digital Mammography</td><td align="char" char="." valign="bottom">2019 vs 2020</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="char" char="." valign="bottom">0.00</td><td align="char" char="." valign="bottom">460.68</td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib29">Lehman et al., 2022</xref></td><td align="left" valign="bottom">Preprint</td><td align="left" valign="bottom">Cross sectional</td><td align="left" valign="bottom">USA</td><td align="left" valign="bottom"/><td align="left" valign="bottom">167500000</td><td align="left" valign="bottom">29276</td><td align="left" valign="bottom">Screening database over 5 facilities</td><td align="left" valign="bottom">National</td><td align="left" valign="bottom">Unspecified</td><td align="left" valign="bottom">Digital Mammography</td><td align="char" char="." valign="bottom">2019 vs 2020</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="char" char="." valign="bottom">0.00</td><td align="char" char="." valign="bottom">460.68</td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib31">London et al., 2022</xref></td><td align="left" valign="bottom">Peer- reviewed</td><td align="left" valign="bottom">Cross sectional</td><td align="left" valign="bottom">USA</td><td align="left" valign="bottom"/><td align="left" valign="bottom">167500000</td><td align="left" valign="bottom">34000000 (full study including colorectal cancers)</td><td align="left" valign="bottom">TriNetX Research Network</td><td align="left" valign="bottom">National</td><td align="left" valign="bottom">Unspecified</td><td align="left" valign="bottom">Digital Mammography</td><td align="left" valign="bottom">Jul – Dec 2019 vs Jul – Dec 2020</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="char" char="." valign="bottom">74.54</td><td align="char" char="." valign="bottom">460.68</td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib36">Miller et al., 2021</xref></td><td align="left" valign="bottom">Peer- reviewed</td><td align="left" valign="bottom">Cross sectional</td><td align="left" valign="bottom">USA</td><td align="left" valign="bottom">Virginia</td><td align="left" valign="bottom">2757460</td><td align="left" valign="bottom">Not specified</td><td align="left" valign="bottom">Instituition Database, University of Virginia</td><td align="left" valign="bottom">Regional</td><td align="left" valign="bottom">Unspecified (45 - 70)</td><td align="left" valign="bottom">Digital Mammography</td><td align="left" valign="bottom">Jan – Nov 2019 vs Jan - Nov 2020</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">no data</td><td align="left" valign="bottom">no data</td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib49">Sprague et al., 2021</xref></td><td align="left" valign="bottom">Peer- reviewed</td><td align="left" valign="bottom">Cross sectional</td><td align="left" valign="bottom">USA</td><td align="left" valign="bottom"/><td align="left" valign="bottom">167500000</td><td align="left" valign="bottom">461083</td><td align="left" valign="bottom">62 radiology facilities of Breast Cancer Surveillance Consortium</td><td align="left" valign="bottom">National</td><td align="char" char="ndash" valign="bottom">40–79</td><td align="left" valign="bottom">Digital Mammography</td><td align="left" valign="bottom">Jan-Jul 2019 vs Jan-Jul 2020</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="char" char="." valign="bottom">0.00</td><td align="char" char="." valign="bottom">142.00</td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib39">Nyante et al., 2021</xref></td><td align="left" valign="bottom">Peer- reviewed</td><td align="left" valign="bottom">Cross sectional</td><td align="left" valign="bottom">USA</td><td align="left" valign="bottom">North Carolina</td><td align="left" valign="bottom">5099371</td><td align="left" valign="bottom">42412</td><td align="left" valign="bottom">7 academic and community breast imaging facilities in North Carolina</td><td align="left" valign="bottom">Regional</td><td align="char" char="ndash" valign="bottom">40–79</td><td align="left" valign="bottom">Digital Mammography</td><td align="left" valign="bottom">Modelled Sep 2019 data vs Sep 2020</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="char" char="." valign="bottom">80.27</td><td align="char" char="." valign="bottom">91.26</td></tr></tbody></table><table-wrap-foot><fn><p>England’s and Scotland’s NHS systems are devolved and, therefore, are separate national entities. However, they hold similar screening criterion where breast screening policy in the NHS (across the UK) is that all women aged 50–70 y + 364 d are invited for breast screening once every 3 y.</p></fn><fn id="table1fn2"><label>*</label><p>These infection rates were region-specific and analogous to the region the study involved. If study period was ≤1 mo, only infection data from the first and last week of the period will be collected. If study period was over the whole year of 2020, the earliest available public health data was used (e.g., study period started from January 2020 but data was only available in March, March data used as first interval of analysis). It should be noted that there is reporting bias here as testing rates may differ between countries. These infection incidence rates were based on national/regional data depending on whether the study population originated from an entire nation or a limited region within a nation. (<xref ref-type="bibr" rid="bib17">Dipartimento della Protezione Civile, 2023a</xref>; <xref ref-type="bibr" rid="bib18">Dipartimento della Protezione Civile, 2023b</xref>; <xref ref-type="bibr" rid="bib23">Government of Ontario, 2023</xref>; <xref ref-type="bibr" rid="bib24">Government of the Netherlands, 2023</xref>; <xref ref-type="bibr" rid="bib13">Cooper et al., 2023</xref>; <xref ref-type="bibr" rid="bib26">IARC, 2022</xref>; <xref ref-type="bibr" rid="bib33">Mathieu, 2022</xref>; <xref ref-type="bibr" rid="bib34">MDHHS, 2023</xref>; <xref ref-type="bibr" rid="bib35">Medicaid.gov, 2022</xref>; <xref ref-type="bibr" rid="bib37">NCDHHS, 2023</xref>; <xref ref-type="bibr" rid="bib38">NHS England, 2021</xref>; <xref ref-type="bibr" rid="bib40">OECD, 2021a</xref>; <xref ref-type="bibr" rid="bib43">PAHO, 2020</xref>; <xref ref-type="bibr" rid="bib46">Sciensano, the Belgian Institute for Health, 2023</xref>; <xref ref-type="bibr" rid="bib48">SPICe, 2023</xref>; <xref ref-type="bibr" rid="bib50">State of Michigan, 2020</xref>; <xref ref-type="bibr" rid="bib51">State of North Carolina, 2020</xref>; <xref ref-type="bibr" rid="bib53">The Scottish Government, 2022</xref>; <xref ref-type="bibr" rid="bib56">UK Government, 2023</xref>; <xref ref-type="bibr" rid="bib61">WHO, 2023</xref>; <xref ref-type="bibr" rid="bib60">WHO, 2022</xref>; <xref ref-type="bibr" rid="bib60">WHO, 2022</xref>; <xref ref-type="bibr" rid="bib62">Worldometer, 2022</xref>; <xref ref-type="bibr" rid="bib59">WHO, 2021</xref>; <xref ref-type="bibr" rid="bib63">Yucatan Times, 2021</xref>).</p></fn><fn id="table1fn3"><label>†</label><p>Types of restrictions will include restrictions that were withdrawn at any point of the study period. Restrictions present were classified as per non-pharmacological interventions mentioned by the paper <xref ref-type="bibr" rid="bib30">Li et al., 2021</xref> <italic>‘The Temporal Association of introducing and lifting non-pharmaceutical interventions with the time-varying reproduction number (R) of SARS-COV-2: A modelling study across 131 countries’, The Lancet Infectious Diseases,</italic> if restrictions were introduced/withdrawn during the study period, it will still be indicated as a 'Yes', Data from Oxford COVID-19 policy tracker, devolved state-wide healthcare organization websites in Canada, the USA, and UK was used to assess this.</p></fn><fn id="table1fn4"><label>‡</label><p>Data was unavailable for regions in this country, national restrictions were assessed instead.</p></fn></table-wrap-foot></table-wrap><p>During COVID-19, many countries implemented various mitigation methods to reduce transmission and of course mortality. To summarize these different infection control measures, <xref ref-type="table" rid="table1">Table 1</xref> shows that all 13 countries/nations had international movement controls in place, 23 study-specific regions had internal movement controls, 21 study-specific regions had stay-at home requirements in place, 1 study-specific region (Northern Italy, Emilia Romagna) had public transport closures, 23 study-specific regions had bans on gatherings &gt;10 people, 24 study-specific regions had public events bans in place, 24 study-specific regions had workplace closures in place, and 23 study-specific regions had in-person school closures in place (<xref ref-type="bibr" rid="bib33">Mathieu, 2022</xref>; <xref ref-type="bibr" rid="bib10">CIHI, 2022</xref>; <xref ref-type="bibr" rid="bib11">Commonwealth of Massachusetts, 2021</xref>; <xref ref-type="bibr" rid="bib12">Commonwealth of Virginia, 2023</xref>; <xref ref-type="bibr" rid="bib13">Cooper et al., 2023</xref>; <xref ref-type="bibr" rid="bib48">SPICe, 2023</xref>; <xref ref-type="bibr" rid="bib50">State of Michigan, 2020</xref>; <xref ref-type="bibr" rid="bib51">State of North Carolina, 2020</xref>).</p><p>Analysis of data from all studies was limited from January 1, 2020, to December 31, 2020.</p><sec id="s2-1"><title>Screening volume changes over study period</title><p>Summary data from 17 studies in eight countries reporting breast cancer screening volumes, and data from 106,484,908 women before and after COVID-19 infection control measures were extracted (data from 2017 to 2020 were the comparison time period, <xref ref-type="table" rid="table2">Table 2</xref>; <xref ref-type="bibr" rid="bib19">Doubova et al., 2021</xref>; <xref ref-type="bibr" rid="bib4">Bessa, 2021</xref>; <xref ref-type="bibr" rid="bib44">Ribeiro et al., 2022</xref>; <xref ref-type="bibr" rid="bib9">Chiarelli et al., 2021</xref>; <xref ref-type="bibr" rid="bib32">Losurdo et al., 2022</xref>; <xref ref-type="bibr" rid="bib58">Walker et al., 2021</xref>; <xref ref-type="bibr" rid="bib38">NHS England, 2021</xref>; <xref ref-type="bibr" rid="bib47">Shen et al., 2022</xref>; <xref ref-type="bibr" rid="bib6">BreastScreen Australia, 2020</xref>; <xref ref-type="bibr" rid="bib15">DeGroff et al., 2021</xref>; <xref ref-type="bibr" rid="bib29">Lehman et al., 2022</xref>; <xref ref-type="bibr" rid="bib1">Amornsiripanitch et al., 2021</xref>; <xref ref-type="bibr" rid="bib49">Sprague et al., 2021</xref>; <xref ref-type="bibr" rid="bib31">London et al., 2022</xref>; <xref ref-type="bibr" rid="bib36">Miller et al., 2021</xref>; <xref ref-type="bibr" rid="bib39">Nyante et al., 2021</xref>; <xref ref-type="bibr" rid="bib2">Becker et al., 2021</xref>). Most studies that showed calendar period trends of screening volume noted temporal variation with declines especially at the height of the pandemic between March and May 2020. In countries with national screening programs, a negative change in screening volume was reported, with the lowest volume change estimated at –12.86% in Australia (<xref ref-type="bibr" rid="bib6">BreastScreen Australia, 2020</xref>), followed by –15.80% in England (<xref ref-type="bibr" rid="bib38">NHS England, 2021</xref>). A larger negative change in screening volume was observed in Brazil (–41.49%) (<xref ref-type="bibr" rid="bib44">Ribeiro et al., 2022</xref>) and Mexico (–61.30%) (<xref ref-type="bibr" rid="bib19">Doubova et al., 2021</xref>). It should be noted that Brazil and Mexico have a lower proportion of population-based breast screening coverage relative to other countries; Brazil having coverage of ~24% and Mexico having ~20% coverage of the eligible population (<xref ref-type="bibr" rid="bib40">OECD, 2021a</xref>; <xref ref-type="bibr" rid="bib57">Unger-Saldaña et al., 2020</xref>). A significant proportion of breast screening in Brazil and Mexico consists of opportunistic screening programs.</p><table-wrap id="table2" position="float"><label>Table 2.</label><caption><title>Breast cancer screening volumes change among 106,484,908 subjects from eight countries.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" colspan="8">Percentage change in volume of breast cancer screening (N = 17)</th></tr><tr><th align="left" valign="bottom">Study</th><th align="left" valign="bottom">Country</th><th align="left" valign="bottom">Region</th><th align="left" valign="bottom">National/regional (scope of study population<xref ref-type="table-fn" rid="table2fn2">*</xref>)</th><th align="left" valign="bottom">Type of breast screening program employed within the study population</th><th align="left" valign="bottom">Sample size</th><th align="left" valign="bottom">Screening timeframe comparison</th><th align="left" valign="bottom">Volume change relative to non-COVID-19 period (%)</th></tr></thead><tbody><tr><td align="left" valign="bottom" colspan="8"><italic>Europe (n = 2)</italic></td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib32">Losurdo et al., 2022</xref></td><td align="left" valign="bottom">Italy</td><td align="left" valign="bottom">Friuli Venezia Giulia</td><td align="left" valign="bottom">Regional</td><td align="left" valign="bottom">Population-based screening present in country</td><td align="left" valign="bottom">58,643</td><td align="left" valign="bottom">Oct–Dec 2019 vs. Oct–Dec 2020</td><td align="left" valign="bottom">11.90</td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib38">NHS England, 2021</xref></td><td align="left" valign="bottom">UK</td><td align="left" valign="bottom">England</td><td align="left" valign="bottom">National</td><td align="left" valign="bottom">Population-based screening present in country</td><td align="left" valign="bottom">3,420,000</td><td align="left" valign="bottom">Monthly average 2019 vs. monthly average 2020</td><td align="left" valign="bottom">15.80</td></tr><tr><td align="left" valign="bottom" colspan="8"><italic>Oceania (n = 1)</italic></td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib6">BreastScreen Australia, 2020</xref></td><td align="left" valign="bottom">Australia</td><td align="left" valign="bottom">NA</td><td align="left" valign="bottom">National</td><td align="left" valign="bottom">Population-based screening present in country</td><td align="left" valign="bottom">802,146</td><td align="left" valign="bottom">May–Sep 2018 vs. May–Sep 2020</td><td align="left" valign="bottom">12.88</td></tr><tr><td align="left" valign="bottom" colspan="8"><italic>Asia (n = 1)</italic></td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib47">Shen et al., 2022</xref></td><td align="left" valign="bottom">China</td><td align="left" valign="bottom">Taiwan</td><td align="left" valign="bottom">Regional</td><td align="left" valign="bottom">Population-based screening present in country</td><td align="left" valign="bottom">699,911</td><td align="left" valign="bottom">Jan–Apr 2019 vs. Jan–Apr 2020</td><td align="left" valign="bottom">22.07</td></tr><tr><td align="left" valign="bottom" colspan="8"><italic>America (n = 13)</italic></td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib4">Bessa, 2021</xref></td><td align="left" valign="bottom">Brazil</td><td align="left" valign="bottom">NA</td><td align="left" valign="bottom">National</td><td align="left" valign="bottom">Population-based screening present in country<xref ref-type="table-fn" rid="table2fn3"><sup>†</sup></xref></td><td align="left" valign="bottom">(2019: 20,636,636; 2020: 21,140,958)</td><td align="left" valign="bottom">2019 vs. 2020</td><td align="left" valign="bottom">42.72</td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib44">Ribeiro et al., 2022</xref></td><td align="left" valign="bottom">Brazil</td><td align="left" valign="bottom">NA</td><td align="left" valign="bottom">National</td><td align="left" valign="bottom">Population-based screening present in country but private sector databases included Brazilian National Health Service (SUS), Outpatient Information System (SIA/SUS), SUS Hospital Information System (SIH/SUS), High Complexity Procedure Authorizations database (APAC), Cancer Information System (ISCAN)</td><td align="left" valign="bottom">5,996,798</td><td align="left" valign="bottom">Jul–Dec 2019 vs. Jul–Dec 2020</td><td align="left" valign="bottom">41.49</td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib19">Doubova et al., 2021</xref></td><td align="left" valign="bottom">Mexico</td><td align="left" valign="bottom">NA</td><td align="left" valign="bottom">National</td><td align="left" valign="bottom">Population-based screening present in country <xref ref-type="table-fn" rid="table2fn4"><sup>‡</sup></xref></td><td align="left" valign="bottom">1,431,216</td><td align="left" valign="bottom">Jan 2019–Mar 2020 vs. Apr–Dec 2020</td><td align="left" valign="bottom">61.30</td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib9">Chiarelli et al., 2021</xref></td><td align="left" valign="bottom">Canada</td><td align="left" valign="bottom">Ontario</td><td align="left" valign="bottom">Regional</td><td align="left" valign="bottom">Population-based screening present in country</td><td align="left" valign="bottom">426,967</td><td align="left" valign="bottom">Jul–Dec 2019 vs. Jul–Dec 2020</td><td align="left" valign="bottom">31.30</td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib58">Walker et al., 2021</xref></td><td align="left" valign="bottom">Canada</td><td align="left" valign="bottom">Ontario</td><td align="left" valign="bottom">Regional</td><td align="left" valign="bottom">Population-based screening present in country</td><td align="left" valign="bottom">890,131</td><td align="left" valign="bottom">Modeled 2019 data vs. Dec 2020</td><td align="left" valign="bottom">22.80</td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib29">Lehman et al., 2022</xref></td><td align="left" valign="bottom">USA</td><td align="left" valign="bottom">NA</td><td align="left" valign="bottom">National</td><td align="left" valign="bottom">Privatized system with mix of national and private insurance usage</td><td align="left" valign="bottom">29,276</td><td align="left" valign="bottom">2019 vs. 2020</td><td align="left" valign="bottom">36.50</td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib36">Miller et al., 2021</xref></td><td align="left" valign="bottom">USA</td><td align="left" valign="bottom">North Carolina</td><td align="left" valign="bottom">Regional</td><td align="left" valign="bottom">Privatized system with mix of national and private insurance usage</td><td align="left" valign="bottom">8,536,000</td><td align="left" valign="bottom">Jan–Nov 2019 vs. Jan–Nov 2020</td><td align="left" valign="bottom">9.80</td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib1">Amornsiripanitch et al., 2021</xref></td><td align="left" valign="bottom">USA</td><td align="left" valign="bottom">Massachusetts</td><td align="left" valign="bottom">Regional</td><td align="left" valign="bottom">Privatized system with mix of national and private insurance usage</td><td align="left" valign="bottom">32,387</td><td align="left" valign="bottom">Jun–Aug 2019 vs. Jun–Aug 2020</td><td align="left" valign="bottom">10.50</td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib31">London et al., 2022</xref></td><td align="left" valign="bottom">USA</td><td align="left" valign="bottom">NA</td><td align="left" valign="bottom">National</td><td align="left" valign="bottom">Privatized system with mix of national and private insurance usage</td><td align="left" valign="bottom">34,000,000</td><td align="left" valign="bottom">Dec 2019 vs. Dec 2020</td><td align="left" valign="bottom">20.00</td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib15">DeGroff et al., 2021</xref></td><td align="left" valign="bottom">USA</td><td align="left" valign="bottom">NA</td><td align="left" valign="bottom">National</td><td align="left" valign="bottom">The National Breast and Cervical Cancer Early Detection Program (NBCCEDP) that provides cancer screening services to women with low income and inadequate health insurance</td><td align="left" valign="bottom">630,264</td><td align="left" valign="bottom">Jun 2019 vs. Jun 2020</td><td align="left" valign="bottom">39.00</td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib2">Becker et al., 2021</xref></td><td align="left" valign="bottom">USA</td><td align="left" valign="bottom">Michigan</td><td align="left" valign="bottom">Regional</td><td align="left" valign="bottom">Health Managed Care Organization (HMO)-based screening (database covers HMO data from Michigan)</td><td align="left" valign="bottom">7,250,080</td><td align="left" valign="bottom">Dec 2019 vs. Dec 2020</td><td align="left" valign="bottom">18.10</td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib49">Sprague et al., 2021</xref></td><td align="left" valign="bottom">USA</td><td align="left" valign="bottom">NA</td><td align="left" valign="bottom">National</td><td align="left" valign="bottom">Privatized system with mix of national and private insurance usage</td><td align="left" valign="bottom">461,083</td><td align="left" valign="bottom">Jul 2019 vs. Jul 2020</td><td align="left" valign="bottom">10.30 (–20.40 to 6.60)</td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib39">Nyante et al., 2021</xref></td><td align="left" valign="bottom">USA</td><td align="left" valign="bottom">North Carolina</td><td align="left" valign="bottom">Regional</td><td align="left" valign="bottom">Privatized system with mix of national and private insurance usage</td><td align="left" valign="bottom">42,412</td><td align="left" valign="bottom">Modeled Sep 2019 data vs. Sep 2020</td><td align="left" valign="bottom">9.00</td></tr></tbody></table><table-wrap-foot><fn><p>NA indicates not applicable. For studies conducted in the USA, ACS guidelines were used as the data collection comparator starting point where March–June 2020 was considered to be a suspension in screening.</p></fn><fn id="table2fn2"><label>*</label><p>This column highlights the origin of the study population in which whether it was drawn from a specific region within a nation, or if the study population was drawn from the entire country.</p></fn><fn id="table2fn3"><label>†</label><p>The study population from this specific study (<xref ref-type="bibr" rid="bib4">Bessa, 2021</xref>) was solely drawn from a national population-based screening database in Brazil. It should be noted that Brazil has a lower proportion of population-based breast screening coverage relative to other countries; having a coverage of 24% in the eligible population (<xref ref-type="bibr" rid="bib57">Unger-Saldaña et al., 2020</xref>).</p></fn><fn id="table2fn4"><label>‡</label><p>It should be noted that Mexico has a lower proportion of population-based breast screening coverage relative to other countries due to recent introduction; having ~20% coverage of the eligible population (<xref ref-type="bibr" rid="bib41">OECD, 2021b</xref>; <xref ref-type="bibr" rid="bib43">PAHO, 2020</xref>).</p></fn></table-wrap-foot></table-wrap><p>In the USA, which has mix of insurance providers there was a wide range of change in screening volume. Using data from Health Managed Organization (HMO) Blue Cross Blue Shield (BCBS) from the state of Michigan, the authors observed temporal changes in rates with an increase slightly above 2019 levels in the last few months of 2020, with an 18.10% overall increase in screening volume (<xref ref-type="bibr" rid="bib2">Becker et al., 2021</xref>). Although rates were above 2019 levels, the authors noted that the odds that a woman received breast cancer screening remained 20% lower in 2020 relative to 2019 (<xref ref-type="bibr" rid="bib2">Becker et al., 2021</xref>). This was consistent with the decrease in screening volume that was generally observed from six studies with data among populations wholly or partially covered by national insurance (<xref ref-type="bibr" rid="bib29">Lehman et al., 2022</xref>; <xref ref-type="bibr" rid="bib1">Amornsiripanitch et al., 2021</xref>; <xref ref-type="bibr" rid="bib49">Sprague et al., 2021</xref>; <xref ref-type="bibr" rid="bib31">London et al., 2022</xref>; <xref ref-type="bibr" rid="bib36">Miller et al., 2021</xref>; <xref ref-type="bibr" rid="bib39">Nyante et al., 2021</xref>). Percentage decreases ranged from –36.50 (<xref ref-type="bibr" rid="bib29">Lehman et al., 2022</xref>) to –9.80% (<xref ref-type="bibr" rid="bib36">Miller et al., 2021</xref>). Data from the USA National Breast and Cervical Cancer Early Detection Program (NBCCEDP), which provides cancer screening services to women with low income and inadequate health insurance, reported a greater decrease (–39.00%) in volume (<xref ref-type="bibr" rid="bib15">DeGroff et al., 2021</xref>). Two other studies had smaller populations with less certainty and wider confidence intervals, with one reporting an 8% increase (<xref ref-type="bibr" rid="bib39">Nyante et al., 2021</xref>) and the other a –10% decline (<xref ref-type="bibr" rid="bib31">London et al., 2022</xref>). In the USA, where there is a mix of national (Medicare) and private insurance depending on age, screening volume changes were similar to other national screening programs at –36.50% (<xref ref-type="bibr" rid="bib29">Lehman et al., 2022</xref>). In contrast, a positive increase in volume was observed among private insurance providers +30% (<xref ref-type="bibr" rid="bib31">London et al., 2022</xref>).</p></sec><sec id="s2-2"><title>Screening participation uptake rate changes</title><p>A total of nine cross-sectional studies reported breast cancer screening participation rates and represented &gt;46,257,402 participants from varying calendar periods across five countries (<xref ref-type="bibr" rid="bib1">Amornsiripanitch et al., 2021</xref>; <xref ref-type="bibr" rid="bib16">Dennis et al., 2021</xref>; <xref ref-type="bibr" rid="bib21">Fedewa et al., 2021</xref>; <xref ref-type="bibr" rid="bib8">Chen et al., 2021</xref>; <xref ref-type="bibr" rid="bib38">NHS England, 2021</xref>; <xref ref-type="bibr" rid="bib7">Campbell et al., 2021</xref>; <xref ref-type="bibr" rid="bib4">Bessa, 2021</xref>; <xref ref-type="bibr" rid="bib5">BreastScreen Aoteroa, 2022</xref>; <xref ref-type="bibr" rid="bib27">Jidkova et al., 2022</xref>). There was considerable variability in change (<xref ref-type="table" rid="table3">Table 3</xref>), ranging from +2–8% in Scotland to –43.54% in Brazil (<xref ref-type="bibr" rid="bib7">Campbell et al., 2021</xref>; <xref ref-type="bibr" rid="bib4">Bessa, 2021</xref>). In the USA, there was a consistent negative change in screening participation uptake rates (<xref ref-type="bibr" rid="bib1">Amornsiripanitch et al., 2021</xref>; <xref ref-type="bibr" rid="bib16">Dennis et al., 2021</xref>; <xref ref-type="bibr" rid="bib21">Fedewa et al., 2021</xref>; <xref ref-type="bibr" rid="bib8">Chen et al., 2021</xref>).</p><table-wrap id="table3" position="float"><label>Table 3.</label><caption><title>Breast cancer screening participation uptake rates change from nine studies from five countries.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" colspan="8">Percentage change in participation uptake rate of breast cancer screening (N = 9)</th></tr><tr><th align="left" valign="bottom">Study</th><th align="left" valign="bottom">Country</th><th align="left" valign="bottom">Region</th><th align="left" valign="bottom">National/regional (scope of study population)<xref ref-type="table-fn" rid="table3fn2">*</xref></th><th align="left" valign="bottom">Type of breast screening program employed within the study population</th><th align="left" valign="bottom">Sample size</th><th align="left" valign="bottom">Screening timeframe comparison</th><th align="left" valign="bottom">Participation rate change relative to non-COVID-19 period</th></tr></thead><tbody><tr><td align="left" valign="bottom" colspan="8"><italic>Europe (n = 3)</italic></td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib38">NHS England, 2021</xref></td><td align="left" valign="bottom">UK</td><td align="left" valign="bottom">England</td><td align="left" valign="bottom">National</td><td align="left" valign="bottom">Population-based screening available in country</td><td align="left" valign="bottom">3,420,000</td><td align="left" valign="bottom">2019 vs. 2020</td><td align="left" valign="bottom">11.80%</td></tr><tr><td align="left" valign="bottom" rowspan="2"><xref ref-type="bibr" rid="bib7">Campbell et al., 2021</xref></td><td align="left" valign="bottom" rowspan="2">UK</td><td align="left" valign="bottom" rowspan="2">Scotland</td><td align="left" valign="bottom" rowspan="2">National</td><td align="left" valign="bottom" rowspan="2">Population-based screening available in country</td><td align="left" valign="bottom" rowspan="2">NA</td><td align="left" valign="bottom" rowspan="2">Aug–Dec 2019 vs. Aug–Dec 2020 <xref ref-type="table-fn" rid="table3fn4"><sup>‡</sup></xref></td><td align="left" valign="bottom">+10.96% (Aug 2020)</td></tr><tr><td align="left" valign="bottom">+2–8% (Sep 2020–Mar 2021 vs. Sep 2019– Mar 2020)<xref ref-type="table-fn" rid="table3fn4"><sup>‡</sup></xref></td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib27">Jidkova et al., 2022</xref></td><td align="left" valign="bottom">Belgium</td><td align="left" valign="bottom">Flanders</td><td align="left" valign="bottom">Regional</td><td align="left" valign="bottom">Population-based screening available in country</td><td align="left" valign="bottom">NA</td><td align="left" valign="bottom">Jul–Dec 2019 vs. Jul–Dec 2020</td><td align="left" valign="bottom">1.0% (–1.3; –0.7)</td></tr><tr><td align="left" valign="bottom" colspan="8"><italic>Oceania (n = 1)</italic></td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib5">BreastScreen Aoteroa, 2022</xref></td><td align="left" valign="bottom">New Zealand</td><td align="left" valign="bottom">NA</td><td align="left" valign="bottom">National</td><td align="left" valign="bottom">Population-based screening available in country</td><td align="left" valign="bottom">NA</td><td align="left" valign="bottom">Dec 2018/2019 vs. May–Dec 2020</td><td align="left" valign="bottom">6.70%</td></tr><tr><td align="left" valign="bottom" colspan="8"><italic>Americas (n = 5)</italic></td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib4">Bessa, 2021</xref></td><td align="left" valign="bottom">Brazil</td><td align="left" valign="bottom">NA</td><td align="left" valign="bottom">National</td><td align="left" valign="bottom">Population-based screening available in country<xref ref-type="table-fn" rid="table3fn3"><sup>†</sup></xref></td><td align="left" valign="bottom">(2019: 20,636,636; 2020: 21,140,958)</td><td align="left" valign="bottom">2019 vs. 2020</td><td align="left" valign="bottom">43.54%</td></tr><tr><td align="left" valign="bottom" rowspan="2"><xref ref-type="bibr" rid="bib16">Dennis et al., 2021</xref></td><td align="left" valign="bottom" rowspan="2">USA</td><td align="left" valign="bottom" rowspan="2">NA</td><td align="left" valign="bottom" rowspan="2">National</td><td align="left" valign="bottom" rowspan="2">Privatized system with mix of national and private insurance usage</td><td align="left" valign="bottom" rowspan="2">475,083 (age: 50–74) 117,498 (age: 40–49)</td><td align="left" valign="bottom" rowspan="2">2014–2019 vs. 2020</td><td align="left" valign="bottom">5.30% (50–79)</td></tr><tr><td align="left" valign="bottom">7.20% (40–49)</td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib21">Fedewa et al., 2021</xref></td><td align="left" valign="bottom">USA</td><td align="left" valign="bottom">NA</td><td align="left" valign="bottom">National</td><td align="left" valign="bottom">Privatized system with mix of national and private insurance usage</td><td align="left" valign="bottom">434,840</td><td align="left" valign="bottom">2019 vs. 2020</td><td align="left" valign="bottom">8.00%</td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib1">Amornsiripanitch et al., 2021</xref></td><td align="left" valign="bottom">USA</td><td align="left" valign="bottom">Massachusetts</td><td align="left" valign="bottom">Regional</td><td align="left" valign="bottom">Privatized system with mix of national and private insurance usage</td><td align="left" valign="bottom">32,387</td><td align="left" valign="bottom">Jun–Aug 2019 vs. Jun–Aug 2020</td><td align="left" valign="bottom">14.80%</td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib8">Chen et al., 2021</xref></td><td align="left" valign="bottom">USA</td><td align="left" valign="bottom">NA</td><td align="left" valign="bottom">National</td><td align="left" valign="bottom">Privatized system with mix of national and private insurance usage</td><td align="left" valign="bottom">NA</td><td align="left" valign="bottom">Jul 2019 vs. Jul 2020</td><td align="left" valign="bottom">3.33%</td></tr></tbody></table><table-wrap-foot><fn><p>NA indicates not applicable For studies conducted in the USA, ACS guidelines were used as the data collection comparator starting point where Mar-Jun 2020 was considered to be a suspension in screening.</p></fn><fn id="table3fn2"><label>*</label><p>This column highlights the origin of the study population in which whether it was drawn from a specific region within a nation, or if the study population was drawn from the entire country.</p></fn><fn id="table3fn3"><label>†</label><p>The study population from this specific study (<xref ref-type="bibr" rid="bib4">Bessa, 2021</xref>) was solely drawn from a national population-based screening database in Brazil. It should be noted that Brazil has a lower proportion of population-based breast screening coverage relative to other countries; having a coverage of 24% in the eligible population (<xref ref-type="bibr" rid="bib57">Unger-Saldaña et al., 2020</xref>).</p></fn><fn id="table3fn4"><label>‡</label><p>It should be noted that this study presented a range of values (2–8%) comparing the uptake rate from Sep 2020 to Mar 2021 vs. Sep 2019 to Mar 2020. As the timeframe of Jan–Mar 2021 was not within the scope of the study, we used the point estimate of the uptake rate in Aug 2020 vs. Aug 2019 as our last available data point instead.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s2-3"><title>Study quality</title><p>The quality of the included studies was assessed using the JBI tool (<xref ref-type="table" rid="table4">Table 4</xref>). A weakness across most studies was failure to identify and consider confounding factors. From <xref ref-type="table" rid="table4">Table 4</xref>, 25 studies had no issues defining the inclusion sample. Nineteen studies were clear in defining the study setting and subjects. Studies had no issues quantifying exposure of COVID-19, although this was based on temporality since all healthcare systems globally were affected (<xref ref-type="bibr" rid="bib62">Worldometer, 2022</xref>). All studies apart from <xref ref-type="bibr" rid="bib2">Becker et al., 2021</xref> had no issue measuring the condition through either screening appointment attendance or insurance claims data. Most studies (65%, N = 17) did not define confounding factors regarding measurement of primary outcomes. Regarding comparison of volumes of screening prior to COVID-19 and observed periods, these studies did not provide source of reduction in screening capacity (e.g., due to social distancing or participation uptake). Twenty-three studies failed to provide strategies to address confounding factors (e.g., elucidating reduction in capacity and presenting it as a proportion to overall volume).</p><table-wrap id="table4" position="float"><label>Table 4.</label><caption><title>Summary of results of appraisal of all included studies with Joanna Briggs Institute (JBI) Critical Appraisal Tool for cross-sectional studies.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" colspan="9">JBI Critical Appraisal Tool for cross-sectional studies appraisal table</th></tr><tr><th align="left" valign="bottom">Study</th><th align="left" valign="bottom">Were the criteria for inclusion in the sample clearly defined?</th><th align="left" valign="bottom">Were the study subjects and the setting described in detail?</th><th align="left" valign="bottom">Was the exposure measured in a valid and reliable way?</th><th align="left" valign="bottom">Were objective, standard criteria used for measurement of the condition?</th><th align="left" valign="bottom">Were confounding factors identified?</th><th align="left" valign="bottom">Were strategies to deal with confounding factors stated?</th><th align="left" valign="bottom">Were the outcomes measured in a valid and reliable way?</th><th align="left" valign="bottom">Was appropriate statistical analysis used?</th></tr></thead><tbody><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib1">Amornsiripanitch et al., 2021</xref></td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #E57373;">N</td><td style="background-color: #FFF176;">Unclear</td><td style="background-color: #FFF176;">Unclear</td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib2">Becker et al., 2021</xref></td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #E57373;">N</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #E57373;">N</td><td style="background-color: #E57373;">N</td><td style="background-color: #FFF176;">Unclear</td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib4">Bessa, 2021</xref></td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #FFF176;">Unclear</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #E57373;">N</td><td style="background-color: #E57373;">N</td><td style="background-color: #E57373;">N</td><td style="background-color: #FFF176;">Unclear</td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib7">Campbell et al., 2021</xref></td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #FFF176;">Unclear</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #FFF176;">Unclear</td><td style="background-color: #E57373;">N</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #FFF176;">Unclear</td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib8">Chen et al., 2021</xref></td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #FFF176;">Unclear</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #E57373;">N</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #FFF176;">Unclear</td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib9">Chiarelli et al., 2021</xref></td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #FFF176;">Unclear</td><td style="background-color: #E57373;">N</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #FFF176;">Unclear</td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib15">DeGroff et al., 2021</xref></td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #E57373;">N</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #FFF176;">Unclear</td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib16">Dennis et al., 2021</xref></td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #E57373;">N</td><td style="background-color: #E57373;">N</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #FFF176;">Unclear</td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib19">Doubova et al., 2021</xref></td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #FFF176;">Unclear</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #E57373;">N</td><td style="background-color: #E57373;">N</td><td style="background-color: #E57373;">N</td><td style="background-color: #C5E1A5;">Y</td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib27">Jidkova et al., 2022</xref></td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #FFF176;">Unclear</td><td style="background-color: #E57373;">N</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #FFF176;">Unclear</td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib28">Knoll et al., 2022</xref></td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #E57373;">N</td><td style="background-color: #E57373;">N</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #FFF176;">Unclear</td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib21">Fedewa et al., 2021</xref></td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #E57373;">N</td><td style="background-color: #E57373;">N</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #FFF176;">Unclear</td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib6">BreastScreen Australia, 2020</xref></td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #E57373;">N</td><td style="background-color: #E57373;">N</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #E57373;">N</td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib20">Eijkelboom et al., 2021</xref></td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #FFF176;">Unclear</td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib29">Lehman et al., 2022</xref></td><td style="background-color: #E57373;">N</td><td style="background-color: #E57373;">N</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #E57373;">N</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #FFF176;">Unclear</td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib31">London et al., 2022</xref></td><td style="background-color: #E57373;">N</td><td style="background-color: #E57373;">N</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #E57373;">N</td><td style="background-color: #E57373;">N</td><td style="background-color: #E57373;">N</td><td style="background-color: #FFF176;">Unclear</td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib32">Losurdo et al., 2022</xref></td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #E57373;">N</td><td style="background-color: #E57373;">N</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #FFF176;">Unclear</td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib58">Walker et al., 2021</xref></td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #FFF176;">Unclear</td><td style="background-color: #E57373;">N</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #FFF176;">Unclear</td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib54">Toss et al., 2021</xref></td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #E57373;">N</td><td style="background-color: #E57373;">N</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #FFF176;">Unclear</td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib47">Shen et al., 2022</xref></td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #FFF176;">Unclear</td><td style="background-color: #E57373;">N</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #FFF176;">Unclear</td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib44">Ribeiro et al., 2022</xref></td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #E57373;">N</td><td style="background-color: #E57373;">N</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #FFF176;">Unclear</td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib36">Miller et al., 2021</xref></td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #FFF176;">Unclear</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #E57373;">N</td><td style="background-color: #E57373;">N</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #C5E1A5;">Y</td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib49">Sprague et al., 2021</xref></td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #FFF176;">Unclear</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #C5E1A5;">Y</td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib39">Nyante et al., 2021</xref></td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #C5E1A5;">Y</td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib38">NHS England, 2021</xref></td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #E57373;">N</td><td style="background-color: #E57373;">N</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #E57373;">N</td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib5">BreastScreen Aoteroa, 2022</xref></td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #E57373;">N</td><td style="background-color: #E57373;">N</td><td style="background-color: #C5E1A5;">Y</td><td style="background-color: #E57373;">N</td></tr></tbody></table><table-wrap-foot><fn><p>Green = yes; yellow = unclear; orange = no.</p></fn></table-wrap-foot></table-wrap><p>Four studies (<xref ref-type="bibr" rid="bib4">Bessa, 2021</xref>; <xref ref-type="bibr" rid="bib2">Becker et al., 2021</xref>; <xref ref-type="bibr" rid="bib31">London et al., 2022</xref>; <xref ref-type="bibr" rid="bib19">Doubova et al., 2021</xref>) had unclear reasons for selection of study subjects and control groups (<xref ref-type="bibr" rid="bib31">London et al., 2022</xref>), confounding factors that were not indicated, nor strategies included to solve this. Among these four papers, vague definition of control groups resulted in a poor comparator, resulting in unreliable outcome measures.</p><p>Twenty-three studies provided basic statistical analyses (e.g., mean, adjusted rates per population) with basic data presentation. Statistical analyses were not performed in three government papers (<xref ref-type="bibr" rid="bib6">BreastScreen Australia, 2020</xref>; <xref ref-type="bibr" rid="bib38">NHS England, 2021</xref>; <xref ref-type="bibr" rid="bib5">BreastScreen Aoteroa, 2022</xref>). Twenty-two studies were unclear or did not provide sufficient descriptive statistical analyses regarding comparison of control data to observed data. Statistical analyses were performed in four studies. This includes provision of odds ratios by <xref ref-type="bibr" rid="bib19">Doubova et al., 2021</xref> and <xref ref-type="bibr" rid="bib36">Miller et al., 2021</xref>, Poisson estimation of a 95% confidence interval (95% CI) by <xref ref-type="bibr" rid="bib49">Sprague et al., 2021</xref>, and 95% confidence intervals from comparison of means from <xref ref-type="bibr" rid="bib39">Nyante et al., 2021</xref>.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>We previously reported on modeled evaluations that estimated short- and long-term outcomes for various scenarios and changes in breast screening volume, uptake rates, and breast cancer diagnosis rates (<xref ref-type="bibr" rid="bib22">Figueroa et al., 2021</xref>; <xref ref-type="bibr" rid="bib59">WHO, 2021</xref>). In this rapid review, we show that during COVID-19 there was a generally reported reduction in breast cancer screening volume and participation uptake rate that varied by healthcare setting (e.g., national population-based screening vs. opportunistic or private healthcare). Our data suggests that volume and participation uptake are important metrics that requires monitoring by health systems and could inform prevention and early diagnosis efforts, especially if certain groups are not participating.</p><p>Non-pharmaceutical interventions were essential and effective in containing the spread of COVID-19 in the era without vaccines; these extend to domestic/international movement controls, social distancing, and ban on events and gatherings and workplace/school closure (<xref ref-type="bibr" rid="bib30">Li et al., 2021</xref>; <xref ref-type="bibr" rid="bib52">Talic et al., 2021</xref>). While these measures were important to reduce the mortality directly related to COVID-19, they also had indirect effects on other health services including breast cancer screening. In this rapid review, we provide evidence that screening volume and participation uptake rates were reduced but this reduction varied by region and healthcare system.</p><p>In a systematic review and meta-analysis, data from 72 studies were used to investigate the effectiveness of public health measures in reducing COVID-19 incidence and transmission (<xref ref-type="bibr" rid="bib52">Talic et al., 2021</xref>). The meta-analysis pooled an estimate from eight studies and indicated that handwashing (Relative Risk (RR): 0.47; 95% CI: 0.19–1.12), mask-wearing (RR: 0.47; 95% CI: 0.29–0.75), and physical distancing (RR: 0.75; 95% CI: 0.59–0.95) were associated with the reduction in COVID-19 incidence. The remaining public health measures including quarantine and isolation, universal lockdowns, and closures of borders, schools, and workplaces which could not be included in the meta-analysis were evaluated in a narrative way. The findings validated the effectiveness of both individual and packages of public health measures on the transmission of SARS-CoV-2 and incidence of COVID-19. However, the majority of included studies had moderate risk of bias based on quality assessment. For breast cancer screening, the importance of mitigation measures that emphasized physical distancing to have been the most important in reducing screening, both for general population participation but also at healthcare facilities aiming to reduce transmission (<xref ref-type="bibr" rid="bib22">Figueroa et al., 2021</xref>).</p><p>Reductions in screening capacity due to physical distancing are likely another source for screening volume reductions. Screening capacity reductions were caused by social distancing, staggered appointments, staff exposure to COVID-19, and cleaning measures. This likely resulted in reductions in time allocated for screening to occur (<xref ref-type="bibr" rid="bib58">Walker et al., 2021</xref>; <xref ref-type="bibr" rid="bib49">Sprague et al., 2021</xref>). <xref ref-type="bibr" rid="bib49">Sprague et al., 2021</xref> considered screening capacity when assessing screening volume. Even though screening capacity recovered to pre-pandemic levels in July 2020, screening volume experienced a 10.8% decrease relative to the control period. Reductions in screening capacity were potentially not the sole factor to screening volume reductions. However, most publications included in our rapid review did not collect data regarding screening capacity, so we cannot determine the proportion of change in screening volume that was attributed to either reduction in screening capacity or change in patient willingness to attend screening. Future analyses are needed where both measures are obtained, which would inform what measures are needed (e.g., information campaigns to alleviate patient fears or increase clinical staffing for catch-up of missed appointments).</p><p>Our data supports differences by healthcare system that were particularly evident in data from the USA where there is a mix of private and national healthcare (Medicare) for persons 65+ [<ext-link ext-link-type="uri" xlink:href="https://www.medicare.gov/">https://www.medicare.gov/</ext-link>]. <xref ref-type="bibr" rid="bib15">DeGroff et al., 2021</xref>, who studied populations reliant solely on national health insurance, showed larger screening volume reductions (–39.00%). This was relative to studies focusing solely on populations with private insurances or studies including patients from both groups (–36.50 to +30%). <xref ref-type="bibr" rid="bib1">Amornsiripanitch et al., 2021</xref>, which included national and private insurance patients, corroborate this. Medicaid and Medicare patients had –17.06% screening volume reduction compared to –10.50% experienced by the entire population. <xref ref-type="bibr" rid="bib36">Miller et al., 2021</xref> suggest that opportunity cost of attending breast screening in lower income groups (e.g., employment) may have led to decreased breast screening in such populations. Some literature showed increases in screening volumes (<xref ref-type="bibr" rid="bib39">Nyante et al., 2021</xref>; <xref ref-type="bibr" rid="bib2">Becker et al., 2021</xref>) and uptake rates (<xref ref-type="bibr" rid="bib7">Campbell et al., 2021</xref>). Increased volume (+9%) from <xref ref-type="bibr" rid="bib39">Nyante et al., 2021</xref> could be inconclusive as the observed screening volume was compared against a modeled 2019 population that was used to simulate a 2020 population in the absence of COVID-19. Although this study was robust, limited data collection till September 2020 did not show full extent of change regarding screening volumes after lifting of COVID-19 suspension guidelines in June 2020. From trends explored in study, breast screening rates were possibly recovering in the study population (USA) in late 2020, but more data is required. The Affordable Care Act may have alleviated breast screening cost through health insurance coverage reforms (<xref ref-type="bibr" rid="bib64">Zhao et al., 2020</xref>). However, this does not address other underlying socioeconomic inequalities (e.g., high cost of treatment, time off from work due to sickness). Patients from deprived backgrounds may be fearful of dealing with the consequences of abnormal screening results (e.g., treatment). This may strain patient finances worsened by COVID-19, potentially explaining lower screening volumes and uptake. Future data on patient characteristics including insurance status, socioeconomic, and race/ethnicity could inform targeted campaigns to reduce inequities if disparities exist.</p><p><xref ref-type="bibr" rid="bib2">Becker et al., 2021</xref> showed a screening volume increase after the lifting of COVID-19 suspension guidelines. This study focused on patients who utilize solely private insurance. Patients already paying for services may be more inclined to maximize utilization of coverage. However, this study states that the odds that a woman received breast cancer screening remained 20% lower in 2020 (OR = 0.80 [0.80, 0.81]) relative to 2019. This study scored poorly in the JBI appraisal tool due to poor outcome measurement; it was unclear how the odds ratio was derived, therefore, increasing the risk of bias of this study. Unusual outcome measures were used, that being the claims invoice for the service. This appeared unreliable; it was unclear whether paying for the service equates to a fulfilled appointment. Invoices could be delayed, making it unclear when the screening took place. This study’s evidence quality needs to be increased for results to be conclusive.</p><p><xref ref-type="bibr" rid="bib7">Campbell et al., 2021</xref> state a 10.96% increase in uptake rate in Scotland. This study population (within the study period) solely included patients who had their appointments cancelled in March 2020 due to the first lockdown and high-risk patients. This particular patient group may have an increased urgency to catch up on screening. This could have contributed to the increased uptake rate of screening in Scotland in the study period. The increase in uptake rates could also be attributed to the increased accessibility for patients due to the ‘work-from-home’ model and increased health consciousness due to COVID-19. Neither raw data nor sample size was defined in the study and will require future analysis.</p><p>Due to the inherent weaknesses of a rapid review, certain limitations are present within the study as explored below. However, this study can be expanded upon by various means (also explored below) to further elucidate the global impact of COVID-19 on breast cancer detection and subsequent care. Other limitations include COVID-19 context as an evolving field with fast publication turnovers; more papers could have been published since the review started. This issue could be partially addressed by completing a repeat search with employment of forward and backward citation tracking, while including more gray literature sources apart from governmental databases (e.g., private screening databases). Other limitations included studies had insufficient data for combined analysis regarding COVID-19 waves past December 2020. Additionally, the data obtained was cross-sectional instead of cohort-based; we were unable to analyze trends and recovery in breast cancer screening rates and incidence rates over time. Exclusion of non-English-language literature was a weakness. Many countries with extensive population-based breast screening programs that were affected by COVID-19 in Europe and Asia were unaccounted for; the inclusion of additional data would be useful to clarify the impact of the pandemic on breast cancer screening program uptake. Furthermore, it should also be noted that COVID-19 infection rates were not reported by the included studies and data from governmental/health board websites may not report study-specific region infection rates.</p><p>In summary, screening volume and uptake rates were generally reduced but many studies showed gains over time even if overall a decline in screening volume was observed. These declines were likely due to the first COVID-19 wave where many healthcare facilities paused non-essential services. Volume and uptake reductions of smaller magnitudes were observed, and our data suggest some difference depending on region and healthcare coverage. Access to screening services may increase marginalization of some vulnerable groups in the USA due to the pandemic, and recovery efforts to reduce disparities in access to screening and early diagnosis should be monitored to determine whether prevention services need strengthening. Participation uptake and volume are not conclusive endpoints themselves, and future work from registries and other data sources are needed to determine whether there has been any impact on incidence, stage, and mortality outcomes.</p></sec><sec id="s4" sec-type="methods"><title>Methods</title><p>We performed a rapid review (<xref ref-type="bibr" rid="bib55">Tricco et al., 2015</xref>), where systematic review processes were modified to facilitate project completion within a shortened timeframe. Searches were limited to two databases and English-language governmental gray literature.</p><sec id="s4-1"><title>Literature search</title><p>RL ran a systematic search on ‘Ovid MEDLINE(R) and In-Process, In-Data-Review &amp; Other Non-Indexed Citations’ Database and WHO COVID-19 Literature Database, with entry date limits from January 1, 2020, to March 12, 2022. In brief, we performed the search with MeSH subject headers and free text terms for ‘COVID-19,’ ‘Breast Neoplasms,’ and ‘Mass screening.’ Our search strategies are listed in <xref ref-type="table" rid="table5">Table 5</xref>. We searched gray literature from government health websites known to have data from population-based screening programs. These consisted of the National Cancer Institute (USA), CDC (USA), NHS (National Healthcare Service) UK database, BreastScreen Australia, and BreastScreen Aotearoa New Zealand. We further screened reference lists of the retrieved eligible publications to identify additional relevant studies. An English-language restriction was placed on the searches. Deduplication was carried out as part of upload to Covidence systematic review software, Veritas Health Innovation, Melbourne, Australia. Available at <ext-link ext-link-type="uri" xlink:href="https://www.covidence.org/">https://www.covidence.org/</ext-link>.</p><table-wrap id="table5" position="float"><label>Table 5.</label><caption><title>Search strategies for rapid review of breast cancer participation and volume during COVID.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" colspan="3">Search string for Ovid MEDLINE(R) and In-Process, In-Data-Review &amp; Other Non-Indexed</th></tr><tr><th align="left" valign="bottom" colspan="3">Citations</th></tr><tr><th align="left" valign="bottom">Search number</th><th align="left" valign="bottom">Search domain</th><th align="left" valign="bottom">Search string in: [mp = title, book title, abstract, original title, name of substance word, subject heading word, floating subheading word, keyword heading word, organism supplementary concept word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]</th></tr></thead><tbody><tr><td align="left" valign="bottom">#1</td><td align="left" valign="bottom">COVID-19</td><td align="left" valign="bottom">(COVID-19 OR 2019 novel coronavirus disease OR 2019 novel coronavirus infection OR 2019 ncov disease OR 2019 ncov infection OR 2019-ncov disease OR 2019-ncov diseases OR 2019-ncov infection OR 2019-ncov infections OR covid 19 OR covid 19 pandemic OR covid 19 virus disease OR covid 19 virus infection OR covid-19 OR covid-19 pandemic OR covid-19 pandemics OR covid-19 virus disease OR covid-19 virus diseases OR covid-19 virus infection OR covid-19 virus infections OR covid19 OR coronavirus disease 19 OR coronavirus disease 2019 OR coronavirus disease-19 OR disease 2019, coronavirus OR sars cov 2 infection OR sars coronavirus 2 infection OR sars-cov-2 infection OR sars-cov-2 infections OR severe acute respiratory syndrome coronavirus 2 infection OR disease, 2019-ncov OR disease, covid-19 virus OR infection, 2019-ncov OR infection, covid-19 virus OR infection, sars-cov-2 OR pandemic, covid-19 OR virus disease, covid-19 OR virus infection, covid-19 OR Coronavirus, 2019 Novel OR ncov OR covid* OR coronavirus* OR SARS* OR severe acute respiratory syndrome OR coronavirus pandemic OR coronavirus disease pandemic)</td></tr><tr><td align="left" valign="bottom">#2</td><td align="left" valign="bottom">Breast cancer</td><td align="left" valign="bottom">(Breast Neoplasms OR Breast Carcinoma In Situ OR Carcinoma, Ductal, Breast OR Carcinoma, Lobular OR breast cancer OR breast carcinoma* OR breast malignant neoplasm* OR breast malignant tumo?r* OR breast neoplasm* OR breast tumo?r* OR cancer of breast? OR cancer of the breast? OR mammary carcinoma* OR mammary neoplasm* OR malignant neoplasm? of breast OR malignant tumo?r? of breast OR mammary cancer* OR neoplasm?, breast OR tumo?r, breast OR tumo?rs, breast OR cancer?, breast OR cancer?, mammary OR carcinoma?, human mammary OR carcinoma?, breast OR neoplasm?, human mammary OR breast carcinoma in situ OR lobular carcinoma in situ OR lcis, lobular carcinoma in situ OR mammary ductal carcinoma? OR carcinoma, ductal, breast OR carcinoma, infiltrating duct OR carcinoma, invasive ductal, breast OR carcinoma, mammary ductal OR carcinomas, infiltrating duct OR carcinomas, mammary ductal OR invasive ductal carcinoma, breast OR lobular carcinoma? OR carcinoma?, lobular OR breast* OR breast tumo?r OR breast tumo?rs OR breast malignant tumo?rs OR breast malignan* OR mammary malignan* OR malignant tumo?rs of breast OR neoplasm? of breast OR breast neoplasm OR lcis)</td></tr><tr><td align="left" valign="bottom">#3</td><td align="left" valign="bottom">Mass screening</td><td align="left" valign="bottom">(Mass Screening OR Mass Chest X-ray OR Early Diagnosis OR Early Detection of Cancer OR Mammography OR screening* OR Ultrasonography, Mammary OR Ultrasonography OR mass chest x ray OR mass chest x-ray* OR mass chest xray* OR x-ray, mass chest OR x-rays, mass chest OR xray, mass chest OR xrays, mass chest OR disease early detection OR early detection of disease OR early diagnosis OR diagnosis, early OR cancer early detection OR cancer early diagnosis OR early detection of cancer OR early diagnosis of cancer OR digital breast tomosyntheses OR digital breast tomosynthesis OR x ray breast tomosynthesis OR x-ray breast tomosyntheses OR x-ray breast tomosynthesis OR breast tomosyntheses, digital OR breast tomosyntheses, x-ray OR breast tomosynthesis, digital OR breast tomosynthesis, x-ray OR breast tissue imaging OR mastography OR mass breast xray OR mass breast x-ray OR chest xray OR chest x-ray OR mammogra* OR program* OR ultrasonic* OR echograph* OR echotomograph* OR sonography* OR ultrasonograph* OR ultrasound* OR exam*)</td></tr><tr><td align="left" valign="bottom">#4</td><td align="left" valign="bottom">Search string</td><td align="left" valign="bottom">1 AND 2 AND 3</td></tr><tr><td align="left" valign="bottom">#5</td><td align="left" valign="bottom">Final search string</td><td align="left" valign="bottom">Limit 4 to English language</td></tr><tr><td align="left" valign="bottom" colspan="3"><bold>Search string for WHO COVID-19 Literature Database (updated to March 12, 2022</bold>)</td></tr><tr><td align="left" valign="bottom"><bold>Search number</bold></td><td align="left" valign="bottom"><bold>Search concept</bold></td><td align="left" valign="bottom"><bold>Title, abstract, subject</bold></td></tr><tr><td align="left" valign="bottom">#1</td><td align="left" valign="bottom">Breast cancer</td><td align="left" valign="bottom">((Breast Neoplasms) OR (Breast Carcinoma In Situ) OR (Carcinoma, Ductal, Breast) OR (Carcinoma, Lobular) OR (breast cancer*) OR (breast carcinoma*) OR (breast malignant neoplasm*) OR (breast malignant tumo?r*) OR (breast neoplasm*) OR (breast tumo?r*) OR (cancer of breast?) OR (cancer of the breast?) OR (mammary carcinoma*) OR (mammary neoplasm*) OR (malignant neoplasm? of breast) OR (malignant tumo?r? of breast) OR (mammary cancer*) OR (breast carcinoma in situ) OR (lobular carcinoma in situ) OR (mammary ductal carcinoma*) OR (breast ductal carcinoma*) OR (infiltrating duct carcinoma*) OR (invasive ductal carcinoma) OR (mammary ductal carcinoma*) OR (invasive ductal breast carcinoma) OR (lobular carcinoma*) OR (breast tumo?r*) OR (breast malignant tumo?r*) OR (breast malignan*) OR (mammary malignan*) OR (malignant tumo?rs of breast*) OR (neoplasm? of breast) OR (lcis*))</td></tr><tr><td align="left" valign="bottom">#2</td><td align="left" valign="bottom">Screening</td><td align="left" valign="bottom">((Mass Screening) OR (Mass Chest X-ray) OR (Early Diagnosis) OR (Early Detection of Cancer) OR (Mammography) OR (Ultrasonography, Mammary) OR (Ultrasonography) OR (national screening) OR (screening*) OR (mass chest x ray) OR (mass chest x-ray*) OR (mass chest xray*) OR (mass chest x-ray*) OR (disease early detection) OR (early detection of disease) OR (early diagnosis) OR (diagnosis, early) OR (cancer early detection) OR (cancer early diagnosis) OR (early detection of cancer) OR (early diagnosis of cancer) OR (digital breast tomosyntheses) OR (digital breast tomosynthesis) OR (x ray breast tomosynthesis) OR (x-ray breast tomosyntheses) OR (breast tomosynthesis*) OR (breast tissue imaging) OR (mastography) OR (mass breast xray) OR (mass breast x-ray) OR (chest xray) OR (chest x-ray) OR (mammogra*) OR (program*) OR (ultrasonic*) OR (echograph*) OR (ultrasonographic*) OR (sonography*) OR (echotomograph*) OR (ultrasound*) OR (exam*))</td></tr><tr><td align="left" valign="bottom" rowspan="2">#3</td><td align="left" valign="bottom" rowspan="2">Final search string</td><td align="left" valign="bottom">#1 AND #2</td></tr><tr><td align="left" valign="bottom">English-language filter</td></tr></tbody></table></table-wrap></sec><sec id="s4-2"><title>Inclusion and exclusion criteria</title><p>The Population, Interventions, Comparator, Outcomes, and Study Characteristics (PICOS) model (<xref ref-type="bibr" rid="bib45">Schardt et al., 2007</xref>) was used to determine eligibility criteria. A pilot literature screen (n = 10) was performed by RL with guidance from MD and JF to confirm validity of criteria. The population of focus are women eligible for breast cancer screening programs globally (population-based or opportunistic) or breast screening programs that are a part of the International Screening Cancer Network (ISCN). The intervention investigated involves the introduction of COVID-19 infection control measures. These were assumed to be present globally due to worldwide prevalence of COVID-19 by March 2020, chosen due to the WHO’s declaration of a pandemic. We also added data on infection control measures based on <xref ref-type="bibr" rid="bib30">Li et al., 2021</xref> ‘The Temporal Association of introducing and lifting non-pharmaceutical interventions with the time-varying reproduction number (R) of SARS-COV-2: A modelling study across 131 countries’, <italic>The Lancet Infectious Diseases</italic>, (see ‘Data extraction’ section for more detail). The comparator involved breast cancer screening statistics after COVID-19-related screening shutdown versus an analogous period in the previous years (e.g., comparing statistics in Australia from May to Sep 2020 against data from May to Sep 2018/2019) or any relevant period.</p><p>Outcomes assessed were the percentage change in ‘volume’ of breast screening participation, defined as total number of breast screening procedures; the percentage change in participation ‘uptake rate’ of breast screening program, defined as the percentage of the eligible population who attend screening; and incidence of breast cancer diagnosis. These were obtained through direct data extraction or calculated with data derived from the comparison of values from each comparator period. Full-text, English-language primary papers or governmental published gray literature were included. Studies with data entirely pertaining to diagnostic imaging were excluded or with future modeled data were excluded. All studies focused on women. Studies were required to have data on breast screening following the resumption of breast screening in countries with a screening shutdown.</p></sec><sec id="s4-3"><title>Title, abstract, full-text screen</title><p>Two reviewers (RL, JF) parallelly independently reviewed titles, abstracts, and subsequently full texts based on predefined inclusion and exclusion criteria. Deduplication of articles and screening was performed on Covidence. Conflict resolution was performed by discussion.</p></sec><sec id="s4-4"><title>Data extraction</title><p>Data extraction for each article was conducted by a single reviewer (RL). A second reviewer (WX) then checked for eligibility of extracted data in 70% of the texts. Any conflicts were resolved by a third reviewer (JF). Data relevant to the evidence for population-based or opportunistic breast cancer screening programs during COVID-19 were extracted including citation details, publication type, study design, country, region, population, study setting, screening sample size, screening timeframe, screening volumes change (before/after COVID-19 infection control guidelines), screening participation uptake rates change (before/after COVID-19 infection control guidelines), and breast cancer incidence rates. A standardized data extraction form was created and piloted for extraction of primary outcome measures. Data pertaining to the presence of COVID-19 infection control measures and COVID-19 infection rates within the study region were also collected. We used the categories of infection control measures as presented in <xref ref-type="bibr" rid="bib30">Li et al., 2021</xref> ‘The Temporal Association of introducing and lifting non-pharmaceutical interventions with the time-varying reproduction number (R) of SARS-COV-2: A modelling study across 131 countries.<italic>’</italic> In addition, we pulled data on infection rates collected from the Oxford COVID-19 policy tracker and devolved statewide healthcare organization websites in Canada, the USA, and the UK (<xref ref-type="bibr" rid="bib33">Mathieu, 2022</xref>; <xref ref-type="bibr" rid="bib10">CIHI, 2022</xref>; <xref ref-type="bibr" rid="bib11">Commonwealth of Massachusetts, 2021</xref>; <xref ref-type="bibr" rid="bib12">Commonwealth of Virginia, 2023</xref>; <xref ref-type="bibr" rid="bib13">Cooper et al., 2023</xref>; <xref ref-type="bibr" rid="bib48">SPICe, 2023</xref>; <xref ref-type="bibr" rid="bib50">State of Michigan, 2020</xref>; <xref ref-type="bibr" rid="bib51">State of North Carolina, 2020</xref>).</p><p>COVID-19 infection rates were defined as the incidence of COVID-19 cases within the area of focus per 100,000 people over 7 d (Formula = (Number of new cases within population over 7 days/Total estimated population number) × 100,000). This was collected from the WHO COVID-19 Dashboard and various devolved health agencies of specific regions (<xref ref-type="bibr" rid="bib61">WHO, 2023</xref>; <xref ref-type="bibr" rid="bib56">UK Government, 2023</xref>; <xref ref-type="bibr" rid="bib17">Dipartimento della Protezione Civile, 2023a</xref>; <xref ref-type="bibr" rid="bib23">Government of Ontario, 2023</xref>; <xref ref-type="bibr" rid="bib24">Government of the Netherlands, 2023</xref>; <xref ref-type="bibr" rid="bib34">MDHHS, 2023</xref>; <xref ref-type="bibr" rid="bib34">MDHHS, 2023</xref>; <xref ref-type="bibr" rid="bib53">The Scottish Government, 2022</xref>).</p></sec><sec id="s4-5"><title>Risk-of-bias assessment</title><p>All studies included had cross-sectional designs. We used the JBI Critical Appraisal Tool for cross-sectional studies to assess the risk of bias of each article (<xref ref-type="bibr" rid="bib14">Critical appraisal tools, 2022</xref>). The JBI checklist is available in <xref ref-type="table" rid="table4">Table 4</xref>. The risk of bias for each article was assessed by a single reviewer [RL], and a second reviewer [WX] cross-assessed the results and verified all related judgment and rationales. Discrepancies were resolved through discussion and a joint reassessment of studies.</p></sec><sec id="s4-6"><title>Data synthesis</title><p>Data were synthesized descriptively since a meta-analysis was not appropriate due to heterogeneity of data. Data was collected by comparing outcome measures before and after COVID-19 infection control measures were introduced; this was presumed due to the worldwide prevalence of COVID-19 by March 2020.</p><p>Data were obtained from any point after lifting of COVID-19 breast screening suspension measures until an endpoint of December 31, 2020. If quantitative data was limited or if raw data was unavailable, the last data point of the study was analyzed. This was compared to data from an analogous pre-COVID-19 period in 2018–2019, or if data was unavailable, against any relevant pre-pandemic period. For countries with no breast screening suspension in 2020, data from during COVID-19 was compared with an analogous period of 2018–2019. This phenomenon only occurred in Taiwan, China (<xref ref-type="bibr" rid="bib47">Shen et al., 2022</xref>). A percentage change against the overall comparator period was calculated.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Investigation, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Data curation, Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Data curation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con4"><p>Conceptualization, Supervision, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con5"><p>Conceptualization, Supervision, Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con6"><p>Data curation, Formal analysis, Supervision, Methodology, Writing – original draft, Writing – review and editing</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-85680-mdarchecklist1-v2.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Full descriptive characteristics and data from included cross-sectional studies (n=26).</title></caption><media xlink:href="elife-85680-supp1-v2.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>Source data included as <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>.</p></sec><ack id="ack"><title>Acknowledgements</title><p>This manuscript was prepared or accomplished by Jonine Figueroa in their personal capacity. The opinions expressed in this article are the author’s own and do not reflect the view of the National Institutes of Health, the Department of Health and Human Services, or the United States government.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amornsiripanitch</surname><given-names>N</given-names></name><name><surname>Chikarmane</surname><given-names>SA</given-names></name><name><surname>Bay</surname><given-names>CP</given-names></name><name><surname>Giess</surname><given-names>CS</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Patients characteristics related to screening mammography cancellation and rescheduling rates during the COVID-19 pandemic</article-title><source>Clinical Imaging</source><volume>80</volume><fpage>205</fpage><lpage>210</lpage><pub-id pub-id-type="doi">10.1016/j.clinimag.2021.07.009</pub-id><pub-id pub-id-type="pmid">34340204</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Becker</surname><given-names>NV</given-names></name><name><surname>Moniz</surname><given-names>MH</given-names></name><name><surname>Tipirneni</surname><given-names>R</given-names></name><name><surname>Dalton</surname><given-names>VK</given-names></name><name><surname>Ayanian</surname><given-names>JZ</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Utilization of Women’s Preventive Health Services During the COVID-19 Pandemic</article-title><source>JAMA Health Forum</source><volume>2</volume><elocation-id>e211408</elocation-id><pub-id pub-id-type="doi">10.1001/jamahealthforum.2021.1408</pub-id><pub-id pub-id-type="pmid">35977205</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berry</surname><given-names>DA</given-names></name><name><surname>Cronin</surname><given-names>KA</given-names></name><name><surname>Plevritis</surname><given-names>SK</given-names></name><name><surname>Fryback</surname><given-names>DG</given-names></name><name><surname>Clarke</surname><given-names>L</given-names></name><name><surname>Zelen</surname><given-names>M</given-names></name><name><surname>Mandelblatt</surname><given-names>JS</given-names></name><name><surname>Yakovlev</surname><given-names>AY</given-names></name><name><surname>Habbema</surname><given-names>JDF</given-names></name><name><surname>Feuer</surname><given-names>EJ</given-names></name><collab>Cancer Intervention and Surveillance Modeling Network Collaborators</collab></person-group><year iso-8601-date="2005">2005</year><article-title>Effect of screening and adjuvant therapy on mortality from breast cancer</article-title><source>The New England Journal of Medicine</source><volume>353</volume><fpage>1784</fpage><lpage>1792</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa050518</pub-id><pub-id pub-id-type="pmid">16251534</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bessa</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Breast imaging hindered during covid-19 pandemic, in Brazil</article-title><source>Revista de Saude Publica</source><volume>55</volume><elocation-id>8</elocation-id><pub-id pub-id-type="doi">10.11606/s1518-8787.2021055003375</pub-id><pub-id pub-id-type="pmid">33978114</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="web"><person-group person-group-type="author"><collab>BreastScreen Aoteroa</collab></person-group><year iso-8601-date="2022">2022</year><article-title>Breast Screening</article-title><ext-link ext-link-type="uri" xlink:href="https://www.timetoscreen.nz/breast-screening/">https://www.timetoscreen.nz/breast-screening/</ext-link><date-in-citation iso-8601-date="2022-04-20">April 20, 2022</date-in-citation></element-citation></ref><ref id="bib6"><element-citation publication-type="web"><person-group person-group-type="author"><collab>BreastScreen Australia</collab></person-group><year iso-8601-date="2020">2020</year><article-title>Breast Screening</article-title><ext-link ext-link-type="uri" xlink:href="https://www.aihw.gov.au/reports/cancer-screening/cancer-screening-and-covid-19-in-australia/data">https://www.aihw.gov.au/reports/cancer-screening/cancer-screening-and-covid-19-in-australia/data</ext-link><date-in-citation iso-8601-date="2022-04-20">April 20, 2022</date-in-citation></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campbell</surname><given-names>C</given-names></name><name><surname>Sommerfield</surname><given-names>T</given-names></name><name><surname>Clark</surname><given-names>GRC</given-names></name><name><surname>Porteous</surname><given-names>L</given-names></name><name><surname>Milne</surname><given-names>AM</given-names></name><name><surname>Millar</surname><given-names>R</given-names></name><name><surname>Syme</surname><given-names>T</given-names></name><name><surname>Thomson</surname><given-names>CS</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>COVID-19 and cancer screening in Scotland: A national and coordinated approach to minimising harm</article-title><source>Preventive Medicine</source><volume>151</volume><elocation-id>106606</elocation-id><pub-id pub-id-type="doi">10.1016/j.ypmed.2021.106606</pub-id><pub-id pub-id-type="pmid">34217418</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>RC</given-names></name><name><surname>Haynes</surname><given-names>K</given-names></name><name><surname>Du</surname><given-names>S</given-names></name><name><surname>Barron</surname><given-names>J</given-names></name><name><surname>Katz</surname><given-names>AJ</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Association of Cancer Screening Deficit in the United States With the COVID-19 Pandemic</article-title><source>JAMA Oncology</source><volume>7</volume><fpage>878</fpage><lpage>884</lpage><pub-id pub-id-type="doi">10.1001/jamaoncol.2021.0884</pub-id><pub-id pub-id-type="pmid">33914015</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiarelli</surname><given-names>AM</given-names></name><name><surname>Walker</surname><given-names>MJ</given-names></name><name><surname>Espino-Hernandez</surname><given-names>G</given-names></name><name><surname>Gray</surname><given-names>N</given-names></name><name><surname>Salleh</surname><given-names>A</given-names></name><name><surname>Adhihetty</surname><given-names>C</given-names></name><name><surname>Gao</surname><given-names>J</given-names></name><name><surname>Fienberg</surname><given-names>S</given-names></name><name><surname>Rey</surname><given-names>MA</given-names></name><name><surname>Rabeneck</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Adherence to guidance for prioritizing higher risk groups for breast cancer screening during the COVID-19 pandemic in the Ontario Breast Screening Program: a descriptive study</article-title><source>CMAJ Open</source><volume>9</volume><fpage>E1205</fpage><lpage>E1212</lpage><pub-id pub-id-type="doi">10.9778/cmajo.20200285</pub-id><pub-id pub-id-type="pmid">34933878</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="web"><person-group person-group-type="author"><collab>CIHI</collab></person-group><year iso-8601-date="2022">2022</year><article-title>Canadian COVID-19 Intervention Timeline</article-title><ext-link ext-link-type="uri" xlink:href="https://www.cihi.ca/en/canadian-covid-19-intervention-timeline">https://www.cihi.ca/en/canadian-covid-19-intervention-timeline</ext-link><date-in-citation iso-8601-date="2023-06-03">June 3, 2023</date-in-citation></element-citation></ref><ref id="bib11"><element-citation publication-type="web"><person-group person-group-type="author"><collab>Commonwealth of Massachusetts</collab></person-group><year iso-8601-date="2021">2021</year><article-title>COVID-19 State of emergency, Previously issued emergency orders and guidance associated with the COVID-19 State of Emergency, which terminated on June 15, 2021</article-title><ext-link ext-link-type="uri" xlink:href="https://www.mass.gov/info-details/covid-19-state-of-emergency#:~:text=NOTE%3A%20Governor%20Baker%20ended%20the,is%20listed%20for%20reference%20only">https://www.mass.gov/info-details/covid-19-state-of-emergency#:~:text=NOTE%3A%20Governor%20Baker%20ended%20the,is%20listed%20for%20reference%20only</ext-link><date-in-citation iso-8601-date="2023-06-03">June 3, 2023</date-in-citation></element-citation></ref><ref id="bib12"><element-citation publication-type="web"><person-group person-group-type="author"><collab>Commonwealth of Virginia</collab></person-group><year iso-8601-date="2023">2023</year><article-title>Executive Order No 53</article-title><ext-link ext-link-type="uri" xlink:href="https://www.governor.virginia.gov/media/governorvirginiagov/executive-actions/EO-53-Temporary-Restrictions-Due-To-Novel-Coronavirus-%28COVID-19%29.pdf">https://www.governor.virginia.gov/media/governorvirginiagov/executive-actions/EO-53-Temporary-Restrictions-Due-To-Novel-Coronavirus-%28COVID-19%29.pdf</ext-link><date-in-citation iso-8601-date="2023-06-01">June 1, 2023</date-in-citation></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cooper</surname><given-names>MJ</given-names></name><name><surname>Sornalingam</surname><given-names>S</given-names></name><name><surname>Health</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>The battle to retain GPs: the importance of undergraduate training in general practice</article-title><source>BMJ</source><volume>381</volume><elocation-id>870</elocation-id><pub-id pub-id-type="doi">10.1136/bmj.p870</pub-id><pub-id pub-id-type="pmid">37085171</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="web"><person-group person-group-type="author"><collab>Critical appraisal tools</collab></person-group><year iso-8601-date="2022">2022</year><article-title>Joanna Briggs Institute</article-title><ext-link ext-link-type="uri" xlink:href="https://jbi.global/critical-appraisal-tools">https://jbi.global/critical-appraisal-tools</ext-link><date-in-citation iso-8601-date="2022-12-08">December 8, 2022</date-in-citation></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeGroff</surname><given-names>A</given-names></name><name><surname>Miller</surname><given-names>J</given-names></name><name><surname>Sharma</surname><given-names>K</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Helsel</surname><given-names>W</given-names></name><name><surname>Kammerer</surname><given-names>W</given-names></name><name><surname>Rockwell</surname><given-names>T</given-names></name><name><surname>Sheu</surname><given-names>A</given-names></name><name><surname>Melillo</surname><given-names>S</given-names></name><name><surname>Uhd</surname><given-names>J</given-names></name><name><surname>Kenney</surname><given-names>K</given-names></name><name><surname>Wong</surname><given-names>F</given-names></name><name><surname>Saraiya</surname><given-names>M</given-names></name><name><surname>Richardson</surname><given-names>LC</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>COVID-19 impact on screening test volume through the National Breast and Cervical Cancer early detection program, January-June 2020, in the United States</article-title><source>Preventive Medicine</source><volume>151</volume><elocation-id>106559</elocation-id><pub-id pub-id-type="doi">10.1016/j.ypmed.2021.106559</pub-id><pub-id pub-id-type="pmid">34217410</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dennis</surname><given-names>LK</given-names></name><name><surname>Hsu</surname><given-names>CH</given-names></name><name><surname>Arrington</surname><given-names>AK</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Reduction in Standard Cancer Screening in 2020 throughout the U.S</article-title><source>Cancers</source><volume>13</volume><elocation-id>5918</elocation-id><pub-id pub-id-type="doi">10.3390/cancers13235918</pub-id><pub-id pub-id-type="pmid">34885028</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="web"><person-group person-group-type="author"><collab>Dipartimento della Protezione Civile</collab></person-group><year iso-8601-date="2023">2023a</year><article-title>Development of number of coronavirus cases: Emilia-Romagna, Italy</article-title><ext-link ext-link-type="uri" xlink:href="https://coronalevel.com/Italy/Emilia-Romagna/">https://coronalevel.com/Italy/Emilia-Romagna/</ext-link><date-in-citation iso-8601-date="2023-06-01">June 1, 2023</date-in-citation></element-citation></ref><ref id="bib18"><element-citation publication-type="web"><person-group person-group-type="author"><collab>Dipartimento della Protezione Civile</collab></person-group><year iso-8601-date="2023">2023b</year><article-title>Development of number of coronavirus cases: Friuli Venezia Giulia, Italy</article-title><ext-link ext-link-type="uri" xlink:href="https://coronalevel.com/Italy/Friuli_Venezia_Giulia/">https://coronalevel.com/Italy/Friuli_Venezia_Giulia/</ext-link><date-in-citation iso-8601-date="2023-06-01">June 1, 2023</date-in-citation></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doubova</surname><given-names>SV</given-names></name><name><surname>Leslie</surname><given-names>HH</given-names></name><name><surname>Kruk</surname><given-names>ME</given-names></name><name><surname>Pérez-Cuevas</surname><given-names>R</given-names></name><name><surname>Arsenault</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Disruption in essential health services in Mexico during COVID-19: an interrupted time series analysis of health information system data</article-title><source>BMJ Global Health</source><volume>6</volume><elocation-id>e006204</elocation-id><pub-id pub-id-type="doi">10.1136/bmjgh-2021-006204</pub-id><pub-id pub-id-type="pmid">34470746</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eijkelboom</surname><given-names>AH</given-names></name><name><surname>de Munck</surname><given-names>L</given-names></name><name><surname>Lobbes</surname><given-names>MBI</given-names></name><name><surname>van Gils</surname><given-names>CH</given-names></name><name><surname>Wesseling</surname><given-names>J</given-names></name><name><surname>Westenend</surname><given-names>PJ</given-names></name><name><surname>Guerrero Paez</surname><given-names>C</given-names></name><name><surname>Pijnappel</surname><given-names>RM</given-names></name><name><surname>Verkooijen</surname><given-names>HM</given-names></name><name><surname>Broeders</surname><given-names>MJM</given-names></name><name><surname>Siesling</surname><given-names>S</given-names></name><collab>NABON COVID-19 Consortium and the COVID and Cancer-NL Consortium</collab></person-group><year iso-8601-date="2021">2021</year><article-title>Impact of the suspension and restart of the Dutch breast cancer screening program on breast cancer incidence and stage during the COVID-19 pandemic</article-title><source>Preventive Medicine</source><volume>151</volume><elocation-id>106602</elocation-id><pub-id pub-id-type="doi">10.1016/j.ypmed.2021.106602</pub-id><pub-id pub-id-type="pmid">34217417</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fedewa</surname><given-names>SA</given-names></name><name><surname>Cotter</surname><given-names>MM</given-names></name><name><surname>Wehling</surname><given-names>KA</given-names></name><name><surname>Wysocki</surname><given-names>K</given-names></name><name><surname>Killewald</surname><given-names>R</given-names></name><name><surname>Makaroff</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Changes in breast cancer screening rates among 32 community health centers during the COVID-19 pandemic</article-title><source>Cancer</source><volume>127</volume><fpage>4512</fpage><lpage>4515</lpage><pub-id pub-id-type="doi">10.1002/cncr.33859</pub-id><pub-id pub-id-type="pmid">34436765</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Figueroa</surname><given-names>JD</given-names></name><name><surname>Gray</surname><given-names>E</given-names></name><name><surname>Pashayan</surname><given-names>N</given-names></name><name><surname>Deandrea</surname><given-names>S</given-names></name><name><surname>Karch</surname><given-names>A</given-names></name><name><surname>Vale</surname><given-names>DB</given-names></name><name><surname>Elder</surname><given-names>K</given-names></name><name><surname>Procopio</surname><given-names>P</given-names></name><name><surname>van Ravesteyn</surname><given-names>NT</given-names></name><name><surname>Mutabi</surname><given-names>M</given-names></name><name><surname>Canfell</surname><given-names>K</given-names></name><name><surname>Nickson</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The impact of the Covid-19 pandemic on breast cancer early detection and screening</article-title><source>Preventive Medicine</source><volume>151</volume><elocation-id>106585</elocation-id><pub-id pub-id-type="doi">10.1016/j.ypmed.2021.106585</pub-id><pub-id pub-id-type="pmid">34217412</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="web"><person-group person-group-type="author"><collab>Government of Ontario</collab></person-group><year iso-8601-date="2023">2023</year><article-title>Status of COVID-19 cases in Ontario</article-title><ext-link ext-link-type="uri" xlink:href="https://data.ontario.ca/en/dataset/status-of-covid-19-cases-in-ontario/resource/ed270bb8-340b-41f9-a7c6-e8ef587e6d11">https://data.ontario.ca/en/dataset/status-of-covid-19-cases-in-ontario/resource/ed270bb8-340b-41f9-a7c6-e8ef587e6d11</ext-link><date-in-citation iso-8601-date="2023-06-01">June 1, 2023</date-in-citation></element-citation></ref><ref id="bib24"><element-citation publication-type="web"><person-group person-group-type="author"><collab>Government of the Netherlands</collab></person-group><year iso-8601-date="2023">2023</year><article-title>Confirmed cases: Coronavirus dashboard: Government.nl, Coronavirus Dashboard</article-title><ext-link ext-link-type="uri" xlink:href="https://coronadashboard.government.nl/landelijk/positief-geteste-mensen">https://coronadashboard.government.nl/landelijk/positief-geteste-mensen</ext-link><date-in-citation iso-8601-date="2023-06-01">June 1, 2023</date-in-citation></element-citation></ref><ref id="bib25"><element-citation publication-type="book"><person-group person-group-type="author"><collab>IARC</collab></person-group><year iso-8601-date="2016">2016</year><source>Breast Cancer Screening: IARC Handbooks of Cancer Prevention</source><publisher-name>International Agency for Research on Cancer</publisher-name></element-citation></ref><ref id="bib26"><element-citation publication-type="web"><person-group person-group-type="author"><collab>IARC</collab></person-group><year iso-8601-date="2022">2022</year><article-title>Cancer Today</article-title><ext-link ext-link-type="uri" xlink:href="https://gco.iarc.fr/today/online-analysis-map?v=2020&amp;mode=population&amp;mode_population=continents&amp;population=900&amp;populations=900&amp;key=crude_rate&amp;sex=2&amp;cancer=20&amp;type=2&amp;statistic=1&amp;prevalence=1&amp;population_group=0&amp;ages_group%5B%5D=0&amp;ages_group%5B%5D=17&amp;nb_items=10&amp;group_cancer=1&amp;include_nmsc=0&amp;include_nmsc_other=0&amp;projection=natural-earth&amp;color_palette=default&amp;map_scale=quantile&amp;map_nb_colors=5&amp;continent=0&amp;show_ranking=0&amp;rotate=%255B10%252C0%255D">https://gco.iarc.fr/today/online-analysis-map?v=2020&amp;mode=population&amp;mode_population=continents&amp;population=900&amp;populations=900&amp;key=crude_rate&amp;sex=2&amp;cancer=20&amp;type=2&amp;statistic=1&amp;prevalence=1&amp;population_group=0&amp;ages_group%5B%5D=0&amp;ages_group%5B%5D=17&amp;nb_items=10&amp;group_cancer=1&amp;include_nmsc=0&amp;include_nmsc_other=0&amp;projection=natural-earth&amp;color_palette=default&amp;map_scale=quantile&amp;map_nb_colors=5&amp;continent=0&amp;show_ranking=0&amp;rotate=%255B10%252C0%255D</ext-link><date-in-citation iso-8601-date="2022-04-11">April 11, 2022</date-in-citation></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jidkova</surname><given-names>S</given-names></name><name><surname>Hoeck</surname><given-names>S</given-names></name><name><surname>Kellen</surname><given-names>E</given-names></name><name><surname>le Cessie</surname><given-names>S</given-names></name><name><surname>Goossens</surname><given-names>MC</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Flemish population-based cancer screening programs: impact of COVID-19 related shutdown on short-term key performance indicators</article-title><source>BMC Cancer</source><volume>22</volume><elocation-id>183</elocation-id><pub-id pub-id-type="doi">10.1186/s12885-022-09292-y</pub-id><pub-id pub-id-type="pmid">35177021</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knoll</surname><given-names>K</given-names></name><name><surname>Reiser</surname><given-names>E</given-names></name><name><surname>Leitner</surname><given-names>K</given-names></name><name><surname>Kögl</surname><given-names>J</given-names></name><name><surname>Ebner</surname><given-names>C</given-names></name><name><surname>Marth</surname><given-names>C</given-names></name><name><surname>Tsibulak</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>The impact of COVID-19 pandemic on the rate of newly diagnosed gynecological and breast cancers: a tertiary center perspective</article-title><source>Archives of Gynecology and Obstetrics</source><volume>305</volume><fpage>945</fpage><lpage>953</lpage><pub-id pub-id-type="doi">10.1007/s00404-021-06259-5</pub-id><pub-id pub-id-type="pmid">34559295</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lehman</surname><given-names>CD</given-names></name><name><surname>Mercaldo</surname><given-names>SF</given-names></name><name><surname>Wang</surname><given-names>GX</given-names></name><name><surname>Dontchos</surname><given-names>BN</given-names></name><name><surname>Specht</surname><given-names>MC</given-names></name><name><surname>Lamb</surname><given-names>LR</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Screening Mammography Recovery after COVID-19 Pandemic facility closures: associations of facility access and racial and Ethnic Screening Disparities</article-title><source>AJR. American Journal of Roentgenology</source><volume>218</volume><fpage>988</fpage><lpage>996</lpage><pub-id pub-id-type="doi">10.2214/AJR.21.26890</pub-id><pub-id pub-id-type="pmid">34817192</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Campbell</surname><given-names>H</given-names></name><name><surname>Kulkarni</surname><given-names>D</given-names></name><name><surname>Harpur</surname><given-names>A</given-names></name><name><surname>Nundy</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Nair</surname><given-names>H</given-names></name><collab>Usher Network for COVID-19 Evidence Reviews group</collab></person-group><year iso-8601-date="2021">2021</year><article-title>The temporal association of introducing and lifting non-pharmaceutical interventions with the time-varying reproduction number (R) of SARS-COV-2: a modelling study across 131 countries</article-title><source>The Lancet. Infectious Diseases</source><volume>21</volume><fpage>193</fpage><lpage>202</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(20)30785-4</pub-id><pub-id pub-id-type="pmid">33729915</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>London</surname><given-names>JW</given-names></name><name><surname>Fazio-Eynullayeva</surname><given-names>E</given-names></name><name><surname>Palchuk</surname><given-names>MB</given-names></name><name><surname>McNair</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Evolving effect of the COVID-19 Pandemic on cancer-related encounters</article-title><source>JCO Clinical Cancer Informatics</source><volume>6</volume><elocation-id>e2100200</elocation-id><pub-id pub-id-type="doi">10.1200/CCI.21.00200</pub-id><pub-id pub-id-type="pmid">35258986</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Losurdo</surname><given-names>P</given-names></name><name><surname>Samardzic</surname><given-names>N</given-names></name><name><surname>Di Lenarda</surname><given-names>F</given-names></name><name><surname>de Manzini</surname><given-names>N</given-names></name><name><surname>Giudici</surname><given-names>F</given-names></name><name><surname>Bortul</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>The real-word impact of breast and colorectal cancer surgery during the SARS-CoV-2 pandemic</article-title><source>Updates in Surgery</source><volume>74</volume><fpage>1063</fpage><lpage>1072</lpage><pub-id pub-id-type="doi">10.1007/s13304-021-01212-2</pub-id><pub-id pub-id-type="pmid">34978052</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="web"><person-group person-group-type="author"><name><surname>Mathieu</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Policy responses to the coronavirus pandemic, Our World in Data</article-title><ext-link ext-link-type="uri" xlink:href="https://ourworldindata.org/policy-responses-covid">https://ourworldindata.org/policy-responses-covid</ext-link><date-in-citation iso-8601-date="2023-06-03">June 3, 2023</date-in-citation></element-citation></ref><ref id="bib34"><element-citation publication-type="web"><person-group person-group-type="author"><collab>MDHHS</collab></person-group><year iso-8601-date="2023">2023</year><article-title>Michigan Data Coronavirus</article-title><ext-link ext-link-type="uri" xlink:href="https://www.michigan.gov/coronavirus/stats">https://www.michigan.gov/coronavirus/stats</ext-link><date-in-citation iso-8601-date="2023-06-02">June 2, 2023</date-in-citation></element-citation></ref><ref id="bib35"><element-citation publication-type="web"><person-group person-group-type="author"><collab>Medicaid.gov</collab></person-group><year iso-8601-date="2022">2022</year><article-title>Medicaid Eligibility</article-title><ext-link ext-link-type="uri" xlink:href="https://www.medicaid.gov/">https://www.medicaid.gov/</ext-link><date-in-citation iso-8601-date="2022-04-20">April 20, 2022</date-in-citation></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>MM</given-names></name><name><surname>Meneveau</surname><given-names>MO</given-names></name><name><surname>Rochman</surname><given-names>CM</given-names></name><name><surname>Schroen</surname><given-names>AT</given-names></name><name><surname>Lattimore</surname><given-names>CM</given-names></name><name><surname>Gaspard</surname><given-names>PA</given-names></name><name><surname>Cubbage</surname><given-names>RS</given-names></name><name><surname>Showalter</surname><given-names>SL</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Impact of the COVID-19 pandemic on breast cancer screening volumes and patient screening behaviors</article-title><source>Breast Cancer Research and Treatment</source><volume>189</volume><fpage>237</fpage><lpage>246</lpage><pub-id pub-id-type="doi">10.1007/s10549-021-06252-1</pub-id><pub-id pub-id-type="pmid">34032985</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="web"><person-group person-group-type="author"><collab>NCDHHS</collab></person-group><year iso-8601-date="2023">2023</year><article-title>COVID-19 Cases and Deaths Dashboard</article-title><ext-link ext-link-type="uri" xlink:href="https://covid19.ncdhhs.gov/dashboard/cases-and-deaths">https://covid19.ncdhhs.gov/dashboard/cases-and-deaths</ext-link><date-in-citation iso-8601-date="2023-06-03">June 3, 2023</date-in-citation></element-citation></ref><ref id="bib38"><element-citation publication-type="web"><person-group person-group-type="author"><collab>NHS England</collab></person-group><year iso-8601-date="2021">2021</year><article-title>Breast Screening Programme: National statistics, Official statistics</article-title><ext-link ext-link-type="uri" xlink:href="https://digital.nhs.uk/data-and-information/publications/statistical/breast-screening-programme">https://digital.nhs.uk/data-and-information/publications/statistical/breast-screening-programme</ext-link><date-in-citation iso-8601-date="2022-04-20">April 20, 2022</date-in-citation></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nyante</surname><given-names>SJ</given-names></name><name><surname>Benefield</surname><given-names>TS</given-names></name><name><surname>Kuzmiak</surname><given-names>CM</given-names></name><name><surname>Earnhardt</surname><given-names>K</given-names></name><name><surname>Pritchard</surname><given-names>M</given-names></name><name><surname>Henderson</surname><given-names>LM</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Population-level impact of coronavirus disease 2019 on breast cancer screening and diagnostic procedures</article-title><source>Cancer</source><volume>127</volume><fpage>2111</fpage><lpage>2121</lpage><pub-id pub-id-type="doi">10.1002/cncr.33460</pub-id><pub-id pub-id-type="pmid">33635541</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="web"><person-group person-group-type="author"><collab>OECD</collab></person-group><year iso-8601-date="2021">2021a</year><article-title>Breast cancer screening (mammography), survey data and programme data</article-title><ext-link ext-link-type="uri" xlink:href="https://stats.oecd.org/FileView2.aspx?IDFile=eb5acd7d-2445-401a-b624-62fcdad85091">https://stats.oecd.org/FileView2.aspx?IDFile=eb5acd7d-2445-401a-b624-62fcdad85091</ext-link><date-in-citation iso-8601-date="2022-04-20">April 20, 2022</date-in-citation></element-citation></ref><ref id="bib41"><element-citation publication-type="book"><person-group person-group-type="author"><collab>OECD</collab></person-group><year iso-8601-date="2021">2021b</year><source>Primary Health Care in Brazil, OECD Reviews of Health Systems</source><publisher-loc>Paris</publisher-loc><publisher-name>OECD Publishing</publisher-name><pub-id pub-id-type="doi">10.1787/120e170e-en</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Page</surname><given-names>MJ</given-names></name><name><surname>McKenzie</surname><given-names>JE</given-names></name><name><surname>Bossuyt</surname><given-names>PM</given-names></name><name><surname>Boutron</surname><given-names>I</given-names></name><name><surname>Hoffmann</surname><given-names>TC</given-names></name><name><surname>Mulrow</surname><given-names>CD</given-names></name><name><surname>Shamseer</surname><given-names>L</given-names></name><name><surname>Tetzlaff</surname><given-names>JM</given-names></name><name><surname>Akl</surname><given-names>EA</given-names></name><name><surname>Brennan</surname><given-names>SE</given-names></name><name><surname>Chou</surname><given-names>R</given-names></name><name><surname>Glanville</surname><given-names>J</given-names></name><name><surname>Grimshaw</surname><given-names>JM</given-names></name><name><surname>Hróbjartsson</surname><given-names>A</given-names></name><name><surname>Lalu</surname><given-names>MM</given-names></name><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Loder</surname><given-names>EW</given-names></name><name><surname>Mayo-Wilson</surname><given-names>E</given-names></name><name><surname>McDonald</surname><given-names>S</given-names></name><name><surname>McGuinness</surname><given-names>LA</given-names></name><name><surname>Stewart</surname><given-names>LA</given-names></name><name><surname>Thomas</surname><given-names>J</given-names></name><name><surname>Tricco</surname><given-names>AC</given-names></name><name><surname>Welch</surname><given-names>VA</given-names></name><name><surname>Whiting</surname><given-names>P</given-names></name><name><surname>Moher</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The PRISMA 2020 statement: an updated guideline for reporting systematic reviews</article-title><source>BMJ</source><volume>372</volume><elocation-id>n71</elocation-id><pub-id pub-id-type="doi">10.1136/bmj.n71</pub-id><pub-id pub-id-type="pmid">33782057</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="web"><person-group person-group-type="author"><collab>PAHO</collab></person-group><year iso-8601-date="2020">2020</year><article-title>Mexico Cancer Country Profile</article-title><ext-link ext-link-type="uri" xlink:href="https://www3.paho.org/hq/index.php?option=com_docman&amp;view=download&amp;category_slug=4-cancer-country-profiles-2020&amp;alias=51536-mexico-cancer-profile-2020&amp;Itemid=270&amp;lang=en">https://www3.paho.org/hq/index.php?option=com_docman&amp;view=download&amp;category_slug=4-cancer-country-profiles-2020&amp;alias=51536-mexico-cancer-profile-2020&amp;Itemid=270&amp;lang=en</ext-link><date-in-citation iso-8601-date="2022-04-20">April 20, 2022</date-in-citation></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ribeiro</surname><given-names>CM</given-names></name><name><surname>Correa</surname><given-names>F</given-names></name><name><surname>Migowski</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Short-term effects of the COVID-19 pandemic on cancer screening, diagnosis and treatment procedures in Brazil: a descriptive study, 2019-2020</article-title><source>Epidemiologia e Servicos de Saude</source><volume>31</volume><elocation-id>e2021405</elocation-id><pub-id pub-id-type="doi">10.1590/S1679-49742022000100010</pub-id><pub-id pub-id-type="pmid">35262614</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schardt</surname><given-names>C</given-names></name><name><surname>Adams</surname><given-names>MB</given-names></name><name><surname>Owens</surname><given-names>T</given-names></name><name><surname>Keitz</surname><given-names>S</given-names></name><name><surname>Fontelo</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Utilization of the PICO framework to improve searching PubMed for clinical questions</article-title><source>BMC Medical Informatics and Decision Making</source><volume>7</volume><elocation-id>16</elocation-id><pub-id pub-id-type="doi">10.1186/1472-6947-7-16</pub-id><pub-id pub-id-type="pmid">17573961</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="web"><person-group person-group-type="author"><collab>Sciensano, the Belgian Institute for Health</collab></person-group><year iso-8601-date="2023">2023</year><article-title>COVID-19 epidemiological situation, COVID-19 Sciensano Epistat</article-title><ext-link ext-link-type="uri" xlink:href="https://epistat.sciensano.be/covid/">https://epistat.sciensano.be/covid/</ext-link><date-in-citation iso-8601-date="2023-06-01">June 1, 2023</date-in-citation></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>CT</given-names></name><name><surname>Hsieh</surname><given-names>HM</given-names></name><name><surname>Chang</surname><given-names>YL</given-names></name><name><surname>Tsai</surname><given-names>HY</given-names></name><name><surname>Chen</surname><given-names>FM</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Different impacts of cancer types on cancer screening during COVID-19 pandemic in Taiwan</article-title><source>Journal of the Formosan Medical Association = Taiwan Yi Zhi</source><volume>121</volume><fpage>1993</fpage><lpage>2000</lpage><pub-id pub-id-type="doi">10.1016/j.jfma.2022.02.006</pub-id><pub-id pub-id-type="pmid">35227585</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="web"><person-group person-group-type="author"><collab>SPICe</collab></person-group><year iso-8601-date="2023">2023</year><article-title>Timeline of coronavirus (covid-19) in Scotland, SPICe Spotlight | Solas air SPICe</article-title><ext-link ext-link-type="uri" xlink:href="https://spice-spotlight.scot/2023/05/10/timeline-of-coronavirus-covid-19-in-scotland/">https://spice-spotlight.scot/2023/05/10/timeline-of-coronavirus-covid-19-in-scotland/</ext-link><date-in-citation iso-8601-date="2023-06-03">June 3, 2023</date-in-citation></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sprague</surname><given-names>BL</given-names></name><name><surname>Lowry</surname><given-names>KP</given-names></name><name><surname>Miglioretti</surname><given-names>DL</given-names></name><name><surname>Alsheik</surname><given-names>N</given-names></name><name><surname>Bowles</surname><given-names>EJA</given-names></name><name><surname>Tosteson</surname><given-names>ANA</given-names></name><name><surname>Rauscher</surname><given-names>G</given-names></name><name><surname>Herschorn</surname><given-names>SD</given-names></name><name><surname>Lee</surname><given-names>JM</given-names></name><name><surname>Trentham-Dietz</surname><given-names>A</given-names></name><name><surname>Weaver</surname><given-names>DL</given-names></name><name><surname>Stout</surname><given-names>NK</given-names></name><name><surname>Kerlikowske</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Changes in Mammography use by Women’s Characteristics during the first 5 months of the COVID-19 Pandemic</article-title><source>Journal of the National Cancer Institute</source><volume>113</volume><fpage>1161</fpage><lpage>1167</lpage><pub-id pub-id-type="doi">10.1093/jnci/djab045</pub-id><pub-id pub-id-type="pmid">33778894</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="web"><person-group person-group-type="author"><collab>State of Michigan</collab></person-group><year iso-8601-date="2020">2020</year><article-title>MDHHS issues three-week epidemic order to save lives, protect frontline heroes during fall covid-19 surge</article-title><ext-link ext-link-type="uri" xlink:href="https://www.michigan.gov/coronavirus/news/2020/11/15/mdhhs-issues-three-week-epidemic-order-to-save-lives-protect-frontline-heroes-during-fall-covid-19">https://www.michigan.gov/coronavirus/news/2020/11/15/mdhhs-issues-three-week-epidemic-order-to-save-lives-protect-frontline-heroes-during-fall-covid-19</ext-link><date-in-citation iso-8601-date="2023-06-04">June 4, 2023</date-in-citation></element-citation></ref><ref id="bib51"><element-citation publication-type="web"><person-group person-group-type="author"><collab>State of North Carolina</collab></person-group><year iso-8601-date="2020">2020</year><article-title>COVID-19 Orders</article-title><ext-link ext-link-type="uri" xlink:href="https://www.nc.gov/covid-19/covid-19-orders">https://www.nc.gov/covid-19/covid-19-orders</ext-link><date-in-citation iso-8601-date="2023-06-03">June 3, 2023</date-in-citation></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Talic</surname><given-names>S</given-names></name><name><surname>Shah</surname><given-names>S</given-names></name><name><surname>Wild</surname><given-names>H</given-names></name><name><surname>Gasevic</surname><given-names>D</given-names></name><name><surname>Maharaj</surname><given-names>A</given-names></name><name><surname>Ademi</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>W</given-names></name><name><surname>Mesa-Eguiagaray</surname><given-names>I</given-names></name><name><surname>Rostron</surname><given-names>J</given-names></name><name><surname>Theodoratou</surname><given-names>E</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Motee</surname><given-names>A</given-names></name><name><surname>Liew</surname><given-names>D</given-names></name><name><surname>Ilic</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Effectiveness of public health measures in reducing the incidence of COVID-19, SARS-COV-2 transmission, and COVID-19 mortality: systematic review and meta-analysis</article-title><source>BMJ</source><volume>375</volume><elocation-id>e068302</elocation-id><pub-id pub-id-type="doi">10.1136/bmj-2021-068302</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="web"><person-group person-group-type="author"><collab>The Scottish Government</collab></person-group><year iso-8601-date="2022">2022</year><article-title>Coronavirus (COVID-19): Trends in Daily Data, Scottish Government</article-title><ext-link ext-link-type="uri" xlink:href="https://www.gov.scot/publications/coronavirus-covid-19-trends-in-daily-data/">https://www.gov.scot/publications/coronavirus-covid-19-trends-in-daily-data/</ext-link><date-in-citation iso-8601-date="2023-06-01">June 1, 2023</date-in-citation></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toss</surname><given-names>A</given-names></name><name><surname>Isca</surname><given-names>C</given-names></name><name><surname>Venturelli</surname><given-names>M</given-names></name><name><surname>Nasso</surname><given-names>C</given-names></name><name><surname>Ficarra</surname><given-names>G</given-names></name><name><surname>Bellelli</surname><given-names>V</given-names></name><name><surname>Armocida</surname><given-names>C</given-names></name><name><surname>Barbieri</surname><given-names>E</given-names></name><name><surname>Cortesi</surname><given-names>L</given-names></name><name><surname>Moscetti</surname><given-names>L</given-names></name><name><surname>Piacentini</surname><given-names>F</given-names></name><name><surname>Omarini</surname><given-names>C</given-names></name><name><surname>Andreotti</surname><given-names>A</given-names></name><name><surname>Gambini</surname><given-names>A</given-names></name><name><surname>Battista</surname><given-names>R</given-names></name><name><surname>Dominici</surname><given-names>M</given-names></name><name><surname>Tazzioli</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Two-month stop in mammographic screening significantly impacts on breast cancer stage at diagnosis and upfront treatment in the COVID era</article-title><source>ESMO Open</source><volume>6</volume><elocation-id>100055</elocation-id><pub-id pub-id-type="doi">10.1016/j.esmoop.2021.100055</pub-id><pub-id pub-id-type="pmid">33582382</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tricco</surname><given-names>AC</given-names></name><name><surname>Antony</surname><given-names>J</given-names></name><name><surname>Zarin</surname><given-names>W</given-names></name><name><surname>Strifler</surname><given-names>L</given-names></name><name><surname>Ghassemi</surname><given-names>M</given-names></name><name><surname>Ivory</surname><given-names>J</given-names></name><name><surname>Perrier</surname><given-names>L</given-names></name><name><surname>Hutton</surname><given-names>B</given-names></name><name><surname>Moher</surname><given-names>D</given-names></name><name><surname>Straus</surname><given-names>SE</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>A scoping review of rapid review methods</article-title><source>BMC Medicine</source><volume>13</volume><elocation-id>224</elocation-id><pub-id pub-id-type="doi">10.1186/s12916-015-0465-6</pub-id><pub-id pub-id-type="pmid">26377409</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="web"><person-group person-group-type="author"><collab>UK Government</collab></person-group><year iso-8601-date="2023">2023</year><article-title>Cookies on the UK Coronavirus Dashboard - England Summary, Cases in England</article-title><ext-link ext-link-type="uri" xlink:href="https://coronavirus.data.gov.uk/details/cases?areaType=nation&amp;areaName=England">https://coronavirus.data.gov.uk/details/cases?areaType=nation&amp;areaName=England</ext-link><date-in-citation iso-8601-date="2023-06-01">June 1, 2023</date-in-citation></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Unger-Saldaña</surname><given-names>K</given-names></name><name><surname>Cedano Guadiamos</surname><given-names>M</given-names></name><name><surname>Burga Vega</surname><given-names>AM</given-names></name><name><surname>Anderson</surname><given-names>BO</given-names></name><name><surname>Romanoff</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Delays to diagnosis and barriers to care for breast cancer in Mexico and Peru: A cross sectional study</article-title><source>The Lancet Global Health</source><volume>8</volume><elocation-id>S16</elocation-id><pub-id pub-id-type="doi">10.1016/S2214-109X(20)30157-1</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walker</surname><given-names>MJ</given-names></name><name><surname>Meggetto</surname><given-names>O</given-names></name><name><surname>Gao</surname><given-names>J</given-names></name><name><surname>Espino-Hernández</surname><given-names>G</given-names></name><name><surname>Jembere</surname><given-names>N</given-names></name><name><surname>Bravo</surname><given-names>CA</given-names></name><name><surname>Rey</surname><given-names>M</given-names></name><name><surname>Aslam</surname><given-names>U</given-names></name><name><surname>Sheppard</surname><given-names>AJ</given-names></name><name><surname>Lofters</surname><given-names>AK</given-names></name><name><surname>Tammemägi</surname><given-names>MC</given-names></name><name><surname>Tinmouth</surname><given-names>J</given-names></name><name><surname>Kupets</surname><given-names>R</given-names></name><name><surname>Chiarelli</surname><given-names>AM</given-names></name><name><surname>Rabeneck</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Measuring the impact of the COVID-19 pandemic on organized cancer screening and diagnostic follow-up care in Ontario, Canada: A provincial, population-based study</article-title><source>Preventive Medicine</source><volume>151</volume><elocation-id>106586</elocation-id><pub-id pub-id-type="doi">10.1016/j.ypmed.2021.106586</pub-id><pub-id pub-id-type="pmid">34217413</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="web"><person-group person-group-type="author"><collab>WHO</collab></person-group><year iso-8601-date="2021">2021</year><article-title>Breast cancer</article-title><ext-link ext-link-type="uri" xlink:href="https://www.who.int/news-room/fact-sheets/detail/breast-cancer">https://www.who.int/news-room/fact-sheets/detail/breast-cancer</ext-link><date-in-citation iso-8601-date="2022-04-20">April 20, 2022</date-in-citation></element-citation></ref><ref id="bib60"><element-citation publication-type="web"><person-group person-group-type="author"><collab>WHO</collab></person-group><year iso-8601-date="2022">2022</year><article-title>Cancer Fact Sheet</article-title><ext-link ext-link-type="uri" xlink:href="https://www.who.int/news-room/fact-sheets/detail/cancer">https://www.who.int/news-room/fact-sheets/detail/cancer</ext-link><date-in-citation iso-8601-date="2022-04-20">April 20, 2022</date-in-citation></element-citation></ref><ref id="bib61"><element-citation publication-type="web"><person-group person-group-type="author"><collab>WHO</collab></person-group><year iso-8601-date="2023">2023</year><article-title>WHO coronavirus (COVID-19) dashboard, World Health Organization</article-title><ext-link ext-link-type="uri" xlink:href="https://covid19.who.int/">https://covid19.who.int/</ext-link><date-in-citation iso-8601-date="2023-06-01">June 1, 2023</date-in-citation></element-citation></ref><ref id="bib62"><element-citation publication-type="web"><person-group person-group-type="author"><collab>Worldometer</collab></person-group><year iso-8601-date="2022">2022</year><article-title>COVID-19 Coronavirus Pandemic Meter</article-title><ext-link ext-link-type="uri" xlink:href="https://www.worldometers.info/coronavirus/">https://www.worldometers.info/coronavirus/</ext-link><date-in-citation iso-8601-date="2022-04-20">April 20, 2022</date-in-citation></element-citation></ref><ref id="bib63"><element-citation publication-type="web"><person-group person-group-type="author"><collab>Yucatan Times</collab></person-group><year iso-8601-date="2021">2021</year><article-title>More and more Yucatecan women are visiting IMSS for breast cancer prevention exams</article-title><ext-link ext-link-type="uri" xlink:href="https://www.theyucatantimes.com/2021/10/more-and-more-yucatecan-women-are-visiting-imss-for-breast-cancer-prevention-exams/">https://www.theyucatantimes.com/2021/10/more-and-more-yucatecan-women-are-visiting-imss-for-breast-cancer-prevention-exams/</ext-link><date-in-citation iso-8601-date="2022-04-20">April 20, 2022</date-in-citation></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Mao</surname><given-names>Z</given-names></name><name><surname>Fedewa</surname><given-names>SA</given-names></name><name><surname>Nogueira</surname><given-names>L</given-names></name><name><surname>Yabroff</surname><given-names>KR</given-names></name><name><surname>Jemal</surname><given-names>A</given-names></name><name><surname>Han</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The Affordable Care Act and access to care across the cancer control continuum: A review at 10 years</article-title><source>CA</source><volume>70</volume><fpage>165</fpage><lpage>181</lpage><pub-id pub-id-type="doi">10.3322/caac.21604</pub-id><pub-id pub-id-type="pmid">32202312</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.85680.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Meza</surname><given-names>Rafael</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00jmfr291</institution-id><institution>Univeristy of Michigan</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><related-object id="sa0ro1" object-id-type="id" object-id="10.1101/2023.02.06.23285513" link-type="continued-by" xlink:href="https://sciety.org/articles/activity/10.1101/2023.02.06.23285513"/></front-stub><body><p>This study presents important evidence of the impact of the covid pandemic on breast cancer screening globally but with important variations by healthcare setting. The data analysis is comprehensive, using solid systematic review methods. The results will be of interest to public health policymakers and health care and cancer control practitioners and researchers across the globe.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.85680.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Meza</surname><given-names>Rafael</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00jmfr291</institution-id><institution>Univeristy of Michigan</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Murphy</surname><given-names>Gwen</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/041kmwe10</institution-id><institution>Imperial College London</institution></institution-wrap><country>United Kingdom</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2023.02.06.23285513">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.medrxiv.org/content/10.1101/2023.02.06.23285513v1">the preprint</ext-link> for the benefit of readers; ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;A Rapid review on the COVID-19 Pandemic's Global Impact on Breast Cancer Screening Participation Rates and Volumes from January-December 2020&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 2 peer reviewers, and the evaluation has been overseen by a Reviewing Editor and a Senior Editor. The following individual involved in the review of your submission has agreed to reveal their identity: Gwen Murphy (Reviewer #2).</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>1) Please see the suggestions from reviewer 2 about restructuring the discussion to improve clarity.</p><p>2) Please consider reviewer 2's suggestion about adding information on the type of lockdown in place in each of the regions/places/times covered by each study. This would definitely help the reader to understand the context of each study. I realize it might be difficult, but given its potential value added to the paper, if feasible, please consider adding it.</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>The authors have done a great job in gathering heterogeneous data from a range of sources and summarizing it. With such a range of data and further a range of contexts (different study settings and geographies), I think in some places the complexity is overwhelming the narrative. The paper would be stronger if you could determine what your most important points are and then discuss these in order of importance, particularly in the Discussion. I have some specific comments/questions below.</p><p>– The screening volume metric is described in the Methods as &quot;volume…defined as total number of breast screening procedures&quot; but then in the Tables it is described as % change. As a result, it's hard to interpret what the difference in the two metrics is, particularly in the few studies where both are used. Could you say more about this in the Discussion?</p><p>– In considering the impact of COVID, would it be worth adding a variable on what kind of &quot;lock-down&quot; was in place in that region during that time? This might not be included in all studies but should be readily google-able. I think this would be a strong addition because, as we know, restrictions differed dramatically across regions and countries and were likely the driving force behind the data.</p><p>– The Discussion is difficult to read. Thinking back to the restrictions in place in many countries during this period, many women might reasonably have been prevented from attending their screening because it was too far away, because they couldn't access transport, or because they had lost all childcare support. I don't think fear would necessarily be the reason for the lack of participation and, importantly, you have NO data to suggest this. I would begin your Discussion by restating your findings and then reminding people of the restrictions that were in place during this period and might explain your findings. Your narrative on screening capacity reduction is contradictory and could be seen as naïve – if there are reductions in staffing because of extraordinary constraints and staff illnesses then an information campaign to alleviate patient fears is unlikely to be effective.</p><p>Could you say more in your Discussion about the various study designs and how that might have contributed to the range of findings? Screening reportedly increased in one study but this appears to be a modelling study, what do you think of that?</p><p>The last paragraph of the Discussion is very well constructed and balanced in terms of repeating the main results and suggesting some possible explanations. I would look to reshape the earlier parts of the Discussion to mirror this structure and flow. You could also consider adding a line on the need to look at other screening programs (whether cancer or otherwise) and determine trends and implications there too.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.85680.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1) Please see the suggestions from reviewer 2 about restructuring the discussion to improve clarity.</p></disp-quote><p>We have restructured and edited the discussion as suggested.</p><disp-quote content-type="editor-comment"><p>2) Please consider reviewer 2's suggestion about adding information on the type of lockdown in place in each of the regions/places/times covered by each study. This would definitely help the reader to understand the context of each study. I realize it might be difficult, but given its potential value added to the paper, if feasible, please consider adding it.</p></disp-quote><p>We have added minimum and maximum infection rates within the study period for each country/region (WHO, 2023, UK Government, 2023; <xref ref-type="bibr" rid="bib18">Dipartimento della Protezione Civile, 2023b</xref>; Government of Ontario, 2023; Government of the Netherlands, 2023; MDHHS, 2023; <xref ref-type="bibr" rid="bib37">NCDHHS, 2023</xref>; The Scottish Government, 2022). We did not include average infection rate as data was unavailable/uncertain (predicted/estimated/probable) for certain periods due to limited testing. We have also classified each lockdown restriction as per the Lancet paper (Li, Y. et al. (2020) ‘The Temporal Association of introducing and lifting non-pharmaceutical interventions with the time-varying reproduction number (R) of SARS-COV-2: A modelling study across 131 countries’,) and added them to Table 1. Bibliography and references have been updated accordingly.</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Recommendations for the authors):</p><p>The authors have done a great job in gathering heterogeneous data from a range of sources and summarizing it. With such a range of data and further a range of contexts (different study settings and geographies), I think in some places the complexity is overwhelming the narrative. The paper would be stronger if you could determine what your most important points are and then discuss these in order of importance, particularly in the Discussion. I have some specific comments/questions below.</p></disp-quote><p>We thank the reviewer for the positive feedback and we have updated the discussion to improve clarity and readability.</p><disp-quote content-type="editor-comment"><p>– The screening volume metric is described in the Methods as &quot;volume…defined as total number of breast screening procedures&quot; but then in the Tables it is described as % change. As a result, it's hard to interpret what the difference in the two metrics is, particularly in the few studies where both are used. Could you say more about this in the Discussion?</p></disp-quote><p>We agree with the reviewer regarding the lack of clarity on the presentation of outcomes. We have attempted to standardise the definition of the outcome metrics in the Methods as we tended to use percentage changes in “volume” and “uptake rate” in presentation of our results.</p><disp-quote content-type="editor-comment"><p>– In considering the impact of COVID, would it be worth adding a variable on what kind of &quot;lock-down&quot; was in place in that region during that time? This might not be included in all studies but should be readily google-able. I think this would be a strong addition because, as we know, restrictions differed dramatically across regions and countries and were likely the driving force behind the data.</p></disp-quote><p>We have added minimum and maximum infection rates within the study period for each country/region (WHO, 2023, UK Government, 2023; Dipartimento della Protezione Civile. 2023; Government of Ontario, 2023; Government of the Netherlands, 2023; MDHHS, 2023; MCDHHS, 2023; The Scottish Government, 2022). We did not include average infection rate as data was unavailable/uncertain (predicted/estimated/probable) for certain periods due to limited testing. We have also classified each lockdown restriction as per the Lancet paper (Li, Y. et al. (2020) ‘The Temporal Association of introducing and lifting non-pharmaceutical interventions with the time-varying reproduction number (R) of SARS-COV-2: A modelling study across 131 countries’,) and added them to Table 1. Bibliography and references have been updated accordingly.</p><disp-quote content-type="editor-comment"><p>– The Discussion is difficult to read. Thinking back to the restrictions in place in many countries during this period, many women might reasonably have been prevented from attending their screening because it was too far away, because they couldn't access transport, or because they had lost all childcare support. I don't think fear would necessarily be the reason for the lack of participation and, importantly, you have NO data to suggest this. I would begin your Discussion by restating your findings and then reminding people of the restrictions that were in place during this period and might explain your findings. Your narrative on screening capacity reduction is contradictory and could be seen as naïve – if there are reductions in staffing because of extraordinary constraints and staff illnesses then an information campaign to alleviate patient fears is unlikely to be effective.</p></disp-quote><p>In rereading the discussion we agree with the reviewer that fear not a major driving force and have updated to include mitigation measures as measured in Li, Y 2020 as likely major reasons for change in screening participation and volume.</p><disp-quote content-type="editor-comment"><p>Could you say more in your Discussion about the various study designs and how that might have contributed to the range of findings? Screening reportedly increased in one study but this appears to be a modelling study, what do you think of that?</p></disp-quote><p>We are not clear about the comment on study designs as all were cross-sectional. The one study Nyante et al., was not a microsimulation type modelling study but rather used interrupted time series models which were are a quasi-experimental design used to evaluate the impact of interventions or exposures--in this case the exposure was in the setting of the COVID-19 pandemic and in the absence of the pandemic.</p><disp-quote content-type="editor-comment"><p>The last paragraph of the Discussion is very well constructed and balanced in terms of repeating the main results and suggesting some possible explanations. I would look to reshape the earlier parts of the Discussion to mirror this structure and flow. You could also consider adding a line on the need to look at other screening programs (whether cancer or otherwise) and determine trends and implications there too.</p></disp-quote><p>As suggested we have substantially revised the discussion to include more context and the data we incorporated on mitigation measures as suggested by the reviewer.</p></body></sub-article></article>